CA2218255C - Method of treatment using electroporation-mediated delivery of drugs and genes - Google Patents
Method of treatment using electroporation-mediated delivery of drugs and genes Download PDFInfo
- Publication number
- CA2218255C CA2218255C CA002218255A CA2218255A CA2218255C CA 2218255 C CA2218255 C CA 2218255C CA 002218255 A CA002218255 A CA 002218255A CA 2218255 A CA2218255 A CA 2218255A CA 2218255 C CA2218255 C CA 2218255C
- Authority
- CA
- Canada
- Prior art keywords
- electrodes
- pairs
- needle
- tissue
- electrode
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
- C12M35/02—Electrical or electromagnetic means, e.g. for electroporation or for cell fusion
Abstract
A method for in vivo electrotherapy, or electroporation-mediated therapy, using a needle array apparatus is provided. Treatment of tumors with a combination of electroporation using the apparatus of the invention, and a chemotherapeutic agent, caused regression of tumors in vivo.
Description
METHOD OF TREATMENT USING ELECTROPORATION
MEDIATED DELIVERY OF DRUGS AND GENES
TECHNICAL FIELD
The present invention relates to the treatment of ailments in humans and other mammals, and more particularly, to an improved method and apparatus for the application of controlled electric fields for in vivo delivery of genes and pharmaceutical compounds into live cells of a patient by electroporation.
BACKGROUND ART
In the 1970's it was discovered that electric fields could be used to create pores in cells without causing permanent damage to them. This discovery made possible the insertion of large molecules into cell cytoplasm. It is known that genes and other molecules such as pharmacological compounds can be incorporated into live cells through a process known as electroporation. The genes or other molecules are mixed with the live cells in a buffer medium and short pulses of high electric fields are applied.
The cell membranes are transiently made porous and the genes or molecules enter the cells. There they can modify the genome of the cell.
Electroporation has been recently suggested as one approach to the treatment of certain diseases such as cancer. For example, in the treatment of certain types of cancer with chemotherapy it is necessary to use a high enough dose of a drug to kill the cancer cells without killing an unacceptable high number of normal cells. If the chemotherapy drug could be inserted directly inside the cancer cells, this objective could be achieved.
Some of the best anti-cancer drugs, for example, bleomycin, normally cannot penetrate the membranes of certain cancer cells. However, electroporation makes it possible to insert the bleomycin info the cells.
One therapeutic application of electroporation is for cancer treatment.
' Experiments on laboratory mammals have been carried out and reported as follows:
Okino, M., E. Kensuke, 1990. The Effects of a Single High Voltage Electrical Stimulation with an Anticancer Drub on in vivo Growing Malignant Tumors. Jap.
1 CA 02218255 1997-10-14 _ P:\WP60\USERS\TT~MP2',PATENTS\t'C'P,GEhE55.RPL iZEPLACL,1WE1~T SHEr.T
MEDIATED DELIVERY OF DRUGS AND GENES
TECHNICAL FIELD
The present invention relates to the treatment of ailments in humans and other mammals, and more particularly, to an improved method and apparatus for the application of controlled electric fields for in vivo delivery of genes and pharmaceutical compounds into live cells of a patient by electroporation.
BACKGROUND ART
In the 1970's it was discovered that electric fields could be used to create pores in cells without causing permanent damage to them. This discovery made possible the insertion of large molecules into cell cytoplasm. It is known that genes and other molecules such as pharmacological compounds can be incorporated into live cells through a process known as electroporation. The genes or other molecules are mixed with the live cells in a buffer medium and short pulses of high electric fields are applied.
The cell membranes are transiently made porous and the genes or molecules enter the cells. There they can modify the genome of the cell.
Electroporation has been recently suggested as one approach to the treatment of certain diseases such as cancer. For example, in the treatment of certain types of cancer with chemotherapy it is necessary to use a high enough dose of a drug to kill the cancer cells without killing an unacceptable high number of normal cells. If the chemotherapy drug could be inserted directly inside the cancer cells, this objective could be achieved.
Some of the best anti-cancer drugs, for example, bleomycin, normally cannot penetrate the membranes of certain cancer cells. However, electroporation makes it possible to insert the bleomycin info the cells.
One therapeutic application of electroporation is for cancer treatment.
' Experiments on laboratory mammals have been carried out and reported as follows:
Okino, M., E. Kensuke, 1990. The Effects of a Single High Voltage Electrical Stimulation with an Anticancer Drub on in vivo Growing Malignant Tumors. Jap.
1 CA 02218255 1997-10-14 _ P:\WP60\USERS\TT~MP2',PATENTS\t'C'P,GEhE55.RPL iZEPLACL,1WE1~T SHEr.T
Journal of Surgery. 20: 197-204. Mir, L.M., S. Orlowski, J. Belehradek Jr., and C.
Paoletti. 1991. Electrochemotheragy Potentiation of Antitumor Effect of Bleomycin by Local Electric Pulses. Eur. J. Cancer. 27: 68-72. Clinical trials have been conducted and reported by Mir, L. M., M. Belehradek, C. Domenge, S. Orlowski, B.
Poddevin, et al. 1991. Electrochemotheraw, a novel antitumor treatment: first clinical trial. C.R.
Acad. Sci. Paris. 313: 613-618.
This treatment is carried out by infusing an anticancer drug directly into the tumor and applying an electric field to the tumor between a pair of electrodes. The field strength must be adjusted accurately so that electroporation of the cells of the tumor occurs with minimal or no damage to any normal or healthy cells. This can normally be carried out with external tumors by applying the electrodes to opposite sides of the tumor so that the electric field is between the electrodes. The distance between the electrodes can be measured and a voltage according to the formula E=V/d can then be applied to the electrodes (E=electric .field strength in V/cm; V=voltage in volts; and d=distance in cm). It is not easy to position electrodes to treat internal tumors and measure the distance between them. U. S. Patent, No. 5,439,440 discloses apparatus for in vivo electroporation wherein electrodes needles inserted into a body.
In U. S.
Patent, No. 5,273,525 a syringe for injecting molecules and macromolecules for electroporation utilizes needles for injection which also function as electrodes. This enables the subsurface placement of electrodes into or adjacent tumors so that electric fields can be generated in the tissue for electroporation of the cells of the tumor.
Document WO-A 94/22526 discloses a device that includes a plurality of needle electrodes to be inserted into tissue to be treated and define a treatment volume. The needles form pairs and a switch successively directs pulse from a generator into the different needle pairs.
Studies have also shown that large size nucleotide sequences (up to 630 kb) can be introduced into mammalian cells via electroporation (Eanault, et al., Gene (Amsterdam), 144(21:205, 1994; Nucleic Acids Research, 15(3):1311, 1987;
Knutson, et al., Anal. Biochem., 164:44, 1987; Gibson, et al., EMBO J., 6(8):2457, 1987;
Dower, et al., Genetic Engineering, 12:275, 1990; Mozo, et al., Plant Molecular Biology, 16:917, 1991 ), thereby affording an efficient method of gene therapy, for example.
a Q,:'~~Yll~' P:\WP60~USERS\TEMPS'.PATEN'tS''PC'I'.GENESS.RPL REPLACEMENT SHEET
. .
Paoletti. 1991. Electrochemotheragy Potentiation of Antitumor Effect of Bleomycin by Local Electric Pulses. Eur. J. Cancer. 27: 68-72. Clinical trials have been conducted and reported by Mir, L. M., M. Belehradek, C. Domenge, S. Orlowski, B.
Poddevin, et al. 1991. Electrochemotheraw, a novel antitumor treatment: first clinical trial. C.R.
Acad. Sci. Paris. 313: 613-618.
This treatment is carried out by infusing an anticancer drug directly into the tumor and applying an electric field to the tumor between a pair of electrodes. The field strength must be adjusted accurately so that electroporation of the cells of the tumor occurs with minimal or no damage to any normal or healthy cells. This can normally be carried out with external tumors by applying the electrodes to opposite sides of the tumor so that the electric field is between the electrodes. The distance between the electrodes can be measured and a voltage according to the formula E=V/d can then be applied to the electrodes (E=electric .field strength in V/cm; V=voltage in volts; and d=distance in cm). It is not easy to position electrodes to treat internal tumors and measure the distance between them. U. S. Patent, No. 5,439,440 discloses apparatus for in vivo electroporation wherein electrodes needles inserted into a body.
In U. S.
Patent, No. 5,273,525 a syringe for injecting molecules and macromolecules for electroporation utilizes needles for injection which also function as electrodes. This enables the subsurface placement of electrodes into or adjacent tumors so that electric fields can be generated in the tissue for electroporation of the cells of the tumor.
Document WO-A 94/22526 discloses a device that includes a plurality of needle electrodes to be inserted into tissue to be treated and define a treatment volume. The needles form pairs and a switch successively directs pulse from a generator into the different needle pairs.
Studies have also shown that large size nucleotide sequences (up to 630 kb) can be introduced into mammalian cells via electroporation (Eanault, et al., Gene (Amsterdam), 144(21:205, 1994; Nucleic Acids Research, 15(3):1311, 1987;
Knutson, et al., Anal. Biochem., 164:44, 1987; Gibson, et al., EMBO J., 6(8):2457, 1987;
Dower, et al., Genetic Engineering, 12:275, 1990; Mozo, et al., Plant Molecular Biology, 16:917, 1991 ), thereby affording an efficient method of gene therapy, for example.
a Q,:'~~Yll~' P:\WP60~USERS\TEMPS'.PATEN'tS''PC'I'.GENESS.RPL REPLACEMENT SHEET
. .
DISCLOSURE OF INVENTION
Accordingly, it is a primary object of the present invention to provide an improved apparatus that can be conveniently and effectively positioned to generate ' predetermined electric fields in pre-selected tissue.
It is another principal object of the present invention to provide an improved a apparatus that provides an effective and convenient means for positioning electrodes into tissue for the injection of therapeutic compounds into the tissue and application of electric fields to the tissue.
In accordance with a primary aspect of the present invention an electrode apparatus for the application of electroporation to a portion of the body of a patient, comprises a support member, an array of a plurality of opposed pairs of needle electrodes adjustably mounted on the support member for insertion into tissue at selected positions and distances from one another, and means including a signal generator and switch means for applying an electric signal to selected pairs of the electrodes for 1 ~ generating an electric field of a predetermined strength.
Another aspect of the invention includes needles that function for injection of therapeutic substances into tissue and function as electrodes for generating electric fields for portion of cells of the tissue.
In yet another aspect of the invention is provided a therapeutic method utilizing the needle array apparatus for the treatment of cells, particularly tumor cells.
BRIEF DESCRIPTION OF DRAWING
The objects, advantages and features of this invention will be more readily appreciated from the following detailed description, when read in conjunction with the accompanying drawing, in which:
Fig. 1 is a side elevation view, in section of a needle assembly in accordance with a preferred embodiment of the invention.
Fig. 2 is a bottom view of the embodiment of Fig. 1.
Fig. 3 is an assembly drawing showing a perspective view of an alternate embodiment of the invention .
~~T
yy y'.
Fig. 4 is a perspective view of the embodiment of Fig. 3 shown assembled.
Fig. 5 is a perspective view of a selector switch for the electrode assembly of Fig.4.
Figs. 6a-6c is a diagrammatic illustration of selected contact positions of the switch of Fig. 5.
Fig. 7 is a perspective view of a further embodiment of the invention.
Fig. 8 is a perspective view of a still further embodiment of the invention.
Figs. 9a-9d is a top plan view, illustrating a preferred form of electrodes and sequence of use.
Figs. l0a and l Ob show the tumor volume after 43 days of ECT with bleomycin in Panc-3 xenografted nude mice. (D=drug; E=electroporation) Fig. 11 is an illustration of tumor growth of Panc-3 cells after ECT with bleomycin in nude mice.
Figs. 12a and 12b show the tumor volume after 20 and 34 days of ECT with 1 S bleomycin, respectively, in non-small cell lung carcinoma (NSCLC) xenografted nude mice. (D=drug; E=electroporation) Fig. 13 shows the tumor volume after 34 days of ECT with bleomycin in non-small cell lung carcinoma (NSCLC) xenografted nude mice. The arrow indicates retreatment of one mouse at day 27. (D=drug; E=electroporation) Figs. 14a and 14b show pre-pulse dosing with neocarcinostatin in Panc-3 and NSCLC, respectively, in the nude mouse model.
Figs. 14c and 14d show post-pulse dosing with neocarcinostatin in Panc-3 in the nude mouse model.
BEST MODE FOR CARRYING OUT THE INVENTION
As used herein the term "molecules" includes pharmacological agents, genes, antibodies or other proteins. One human therapeutic application of electroporation consists of infusion of an anticancer drug and electroporation of the drug into the tumor by applying voltage pulses between electrodes disposed on opposite sides of the tumor, called electrochemotherapy (ECT). The present invention was devised primarily for enabling ECT such as that reported by Okino and Mir et al to be carried out on non-?; CA 02218255 1997-10-14 :~.WP60'.USERS\TEMP.'.PATENTS~f'CT'GENESS.ftPL FZEPLACLl'VI~S1~IT SHEET
surface tumors such as those inside the body. However, it may be utilized for other therapeutic applications.
Referring to Fig. 1 of the drawings, a needle assembly for illustrative purposes is illustrated and designated generally by the numeral 10. The needle assembly comprises an elongated tubular support body 12 which is preferably in the form of a hollow stainless steel shaft. A center needle mount 14 is mounted on the lower end of the shaft 12 and has a central bore 16 for receiving and guiding a center needle 18. The shaft 12 includes a needle exit slot 20 through which the needle electrode 18 extends from the interior thereof to the exterior where it is secured by a clamp 22 to the outside of the tube 12.
The upper end of the electrode 18 may be secured to a screw 24 for connection to an electrical circuit. The lower end of the tubular holder 12 includes threats 26 for threatably receiving a collar 28 for mounting a plurality of needles and a stop collar 30 for stopping or locking the collar 28 in position.
A plurality of needles 32 are mounted in grooves 3~. equally spaced around the outer surface of the needle collar 28. This provides a circular array of equally spaced needles, eight in number in the illustrated embodiment. The needles are held in place by a band clamp 36, having the ends clamped together by a screw or nut and bolt 38 which also serves as an electrical connection for the needles. The band clamp directly engages and holds the needles in place.
This electrode assembly is designed to apply electrical energy to living tissue when the needles are inserted into the tissue. The center needle 18 acts as one electrode, such as an anode or cathode, and the other or annular arrangement of needles functions as the opposite electrode. All of these needles are held in fixed positions when the clamps are installed and secured. One or more of the needles may be cannular or tubular in form for injecting molecules of genes, pharmaceutical or other substances into the tissue.
In one mode of operation the center needle should be adjusted in order to achieve the desired tissue penetration. This is done by releasing the pressure of the center needle 30- clamp 22 and sliding the center needle 18 outwardly or inwardly, as seen in Fig. 1, so that it extends from the center needle guide 14 to desired penetration distance. The u;~ ~' F:\WP60\USERS\1'EMP2\PATENTS\I'C11GENESS,RPL REPLACEMENT SHEET
needle is then clamped in position. Thereafter the annular needles 32 are adjusted to achieve the desired penetration into the tissue. This can be accomplished by releasing the pressure of the band clamp 36 and sliding the needles 32 into the desired position.
Minor adjustments can also be made by moving the needle collar 28 toward and away from the end of the shaft 12. A therapeutic substance may be injected into the tissue through one or more of these needles or by a separate means.
After all needles are adjusted to the proper penetration, the shaft 12 is grasped and the needles are inserted into the tissue to the desired depth. Thereafter, a suitable pulse generator is connected to the electrode assembly and the appropriate voltage applied to the electrodes. A suitable quantity of therapeutic substance such as genes or molecules of a suitable chemical or pharmaceutical for treatment of the tissue is injected into the tissue before the voltage is applied.
A modification to this electrode assembly could include a solid non-penetrating electrode (not shown) in place of the center needle. The non-penetrating center electrode could be any suitable shape conductor such as a button or plate attached to the end of the shaft 12 to contact the surface tissue. The annular needle arrangement would be adjusted to penetrate the tissue at the desired depth when the center electrode is resting on a tissue surface. Electrical energy would flow from the penetrating needles through the tissue and to the central electrode on the surface. These arrangements can be utilized to treat near surface tumors where the circular array of electrodes are designed to encircle the tumor. The central electrode is positioned such that the electrical energy flows through the tumor to the central electrode.
Other advantages of this electrode assembly are that all needles 18 and 32 can be independently adjusted to achieve the desired penetration. The needle 28 collar can also be adjusted to position it from the end of the shaft 12 so that insertion of the center and annular needles can be directly observed. In addition, the needle collar 28 can have any size or configuration to encircle the tissue area to be treated. The needles can also be energized in pairs as described relative to Figs. 3-6.
Referring to Figs. 3 and 4 an alternate embodiment of a circular array needle electrode assembly is illustrated and designated generally by the numeral 40.
This needle assembly comprises a circular array of needles 42 through 52, which are mounted in equally spaced relation in a hub 54 mounted on an elongated cylindrical shaft 56.
~.;, _'7_ The hub 54 is preferably of a suitably selected diameter to provide the desired diameter of the arrays to position around a tumor or other tissue to be treated. One or more of the needles may be hollow to enable the injection of molecules of a therapeutic a substance, as will be more fully described hereinafter.
An electrical connector socket assembly comprises a body member 58 having a central opening or bore 60 for receipt of shaft 56 and an annular array of a plurality of sockets 62 through 72 for receipt of the ends of needles 42 through 52. The sockets 62 through 72 electrically connect the needles to leads 74 through 84 which connect to a distributing switch, as will be subsequently described.
The electrical connector socket 58 fits onto shaft 56 with the end of the needles extending into the electrical sockets 62 through 72 for connecting to the leads 74 through 84. The shaft 56 which mounts the needle array hub 54 and the socket assembly 58 mounts onto a holder 86 adapted to be held in the hand. The holder 86 has an elongated cylindrical configuration adapted to be held in the hand for manipulation.
The holder 86 has a forward socket and including a forwardly extending tubular shaft 88 having a bore 90 into which shaft 56 extends while the shaft 88 extends into a bore (not shown) within the connector member 58. The shaft 56 extends into bore 90 and has a annular groove or recess 92 which is engaged by a retainer latch which comprises a transverse plug 94 in a bore 96 biased to one side and including a bore 98 in which the annular slot 92 extends and is retained in the holder. A spring 102 mounted in bore 96 biases plug 94 to the latched position. The shaft 56 may be released for removal by pressing on end 100 of plug 94.
The holder when assembled as shown in Fig. 4 may be grasped in the hand and the needles inserted into a selected tissue area. The needles 42-52 are preferably spaced and positioned to surround the selected tissue of treatment. One or more of the needles 42-52, as previously explained, may be hollow to enable the injection of the desired ~ therapeutic substance. The electrode leads 74-84 are then connected in a preferred arrangement to a rotatable switch assembly, as shown in Fig. 5, which enables the selection of opposed pairs of the needles for activation or the application of the electrical potential.
_g_ The switch assembly designated generally by the numeral 104 comprises a stationary housing 106 which, in the illustrated embodiment, is generally cylindrical in configuration and in which is mounted a rotor 108 with spaced contacts 110 and connected by a pair of conductors 114 and 116 to a pulse power generator 115.
The rotor contacts l 10 and 112 are positioned within housing 106 to engage annular contacts 118, 120, 122, 124, 126 and 128 to which leads 74-84 are connected.
Referring to Figs. 6a, b and c, the rotor 108 has an internal portion having contacts 110 and 112 each of which bridge between two contacts 118-128 to which the leads 74 through 84 are connected to connect the source of power. The internal contacts 110 and 112 rotate with the rotor 108 and can be selectively positioned in conductive relation with pairs of the internal contacts 118-128 to thereby activate opposed pairs of the needle electrodes. This enables the operator to selectively position the electrodes surrounding a selected tissue and to selectively apply the direction of the electrical field as desired for optimum treatment. The rotor 108 enables the field to be selectively generated around or across the tissue from all directions.
Referring to Fig. 7 an alternate embodiment of an electric field generating array of parallel adjustably positionable electrodes, as disclosed in the parent application, is illustrated. The electrode assembly designated generally by the numeral 130 includes a pair of spaced apart arrays 132 and 134 of conductive needle electrodes 136 and 138 mounted on a dielectric carrier or support member 140. The needle array 132 is held in a fixed clamp 142 which allows the needles 136 to be adjusted in depth relative to the support 140.
The needles 138 are mounted in a moveable clamp 146 which is adjustably mounted on support member 140 by a clamp screw 148. The needles 136 and 138 are each provided with a penetration stop 144. The gap spacing clamp screw 148 secures the clamp 146 in selected positions on the support 140. A gap spacing sensor senses the distance between the needle arrays 132 and 134 and generates a signal that is sent to the pulse generator via conductor cable 152. A pulse generator is connected to the needle electrodes by means of cables 154 and 156. ' Referring to Fig. 8, details of a needle holder or template for various arrangements for establishing a spaced pair or parallel arrays of needles is illustrated.
This embodiment comprises a base holder member 158 having a plurality of adjacently positioned parallel slots 160 into which selected needles 162 and 164 may be positioned in selected spaced relation. This holder may serve to mount a pair of oppositely " polarized needle electrodes 162 and 164, as illustrated. These can be selectively positioned in selected space relationship to be disposed on opposite sides of a selected tissue. The needles are clamped into the slots by a clamp or plate 159. In addition, the holder may be used in combination with an additional holder for provision of multiple arrays on opposite sides of a selected tissue. The illustrated needles may be connected by conductors 166 and 168 to a suitable pulse generator.
Referring to Figs. 9a through 9d, an additional aspect of the invention is illustrated. As more clearly illustrated, the combination electrodes may take the form of separate needles 170 and 172 which may be first inserted into or beside a selected tissue area such as on opposite sides of a tumor 194 as illustrated.
Thereafter the needles may be connected to a syringe or other source of molecules and used to inject a selected molecular solution into the tissue area. The needles may be non-conductive and a pair of electrodes 176 and 178, as illustrated in Fig. 9b, are selectively fed through the bore or lumen of the respective needles into the tissue, as illustrated, and thereafter the needle is removed, as shown in Fig. 9c. The electrodes 176 and 178 are each provided with an elongated insulated conductor 180 and 182 with conductive tips 184 and 186.
A pair of conductors 188 and 190 from a suitable power generator may then be connected to the ends of the conductors of the electrodes by micro clamps 192 and 194, as shown in 9d, and an electric potential applied across the electrodes. This generates a field in the tissue and electroporates the cells of the selected tissue, such as a tumor or the like. This electroporation enables the selected molecules to enter the cells of the tissue and more efficiently kill or alter the cells as desired. This form of needle and electrode may be used with any or all the above described assemblies.
These needle electrode assemblies, as above described, enable the in vivo " positioning of electrodes in or adjacent to subsurface tumors or other tissue. While the focus of the present application has been on electrochemotherapy, the embodiment of the subject invention may be applied to other treatments, such as gene therapy of certain organs of the body.
The nature of the electric field to be generated is determined by the nature of the tissue, the size of the selected tissue and its location. It is desirable that the field be as homogenous as possible and of the correct amplitude. Excessive field strength results in lysing of cells, whereas a low field strength results in reduced efficacy.
The electrodes may be mounted and manipulated in many ways including but not limited to those in the parent application. The electrodes may be conveniently manipulated on and by forceps to internal position.
The waveform of the electrical signal provided by the pulse generator can be an exponentially decaying pulse, a square pulse, a unipolar oscillating pulse train or a bipolar oscillating pulse train. The electric field strength can be 0.2kV/cm to 20kV/cm.
The pulse length can be ten ~,s to 100 ms. There can be one to one hundred pulses. Of course, the waveform, electric field strength and pulse duration are also dependent upon the type of cells and the type of molecules that are to enter the cells via electroporation.
The various parameters including electric field strengths required for the electroporation of any known cell is generally available from the many research papers reporting on the subject, as well as from a database maintained by Genetronics, Inc., San Diego, California, assignee of the subject application. The electric fields needed for in vivo cell electroporation, such as ECT, are similar in amplitude to the fields required for cells in vitro. These are in the range of from 100 V/cm to several kV/cm. This has been verified by the inventors own experiments and those of others reported in scientific publications. The first in vivo application of pulsed electric fields in the chemotherapy field to treat tumors was reported in 1987 by Okino in Japan.
Pulse generators for carrying out the procedures described herein are and have been available on the market for a number of years. One suitable signal generator is the ELECTRO CELL MANIPULATOR Model ECM 600 commercially available from GENETRONICS, INC. of San Diego, California, U.S.A. The ECM 600 signal generator generates a pulse from the complete discharge of a capacitor which results in an exponentially decaying waveform. The electric signal generated by this signal generator is characterized by a fast rise time and an exponential tail. In the signal generator, the electroporation pulse length is set by selecting one of ten timing resistors marked R1 through R10. They are active in both High Voltage Mode (HVM) (capacitance fixed at fifty microfarads) and Low Voltage Mode (LVM) (with a capacitance range from 25 to 3,175 microfarads).
The ECM 600 signal generator has a control knob that permits the adjustment of the amplitude of the set charging voltage applied to the internal capacitors from 50 to 500 volts in LVM and from 0.05 to 2.SkV in the HVM. The amplitude of the electrical signal is shown on a display incorporated into the ECM 600 signal generator.
This device further includes a plurality of push button switches for controlling pulse length, in the Low VM mode, by a simultaneous combination of resistors parallel to the output and a bank of seven selectable additive capacitors.
The ECM 600 signal generator also includes a single automatic charge and pulse push button. This button may be depressed to initiate both charging of the internal capacitors to the set voltage and to deliver a pulse to the outside electrodes in an automatic cycle that takes less than five seconds. The manual button may be sequentially pressed to repeatedly apply the predetermined electric field.
Preferably, the therapeutic method of the invention utilizes a square wave pulse electroporation system. For example, the ElectroSquarePorator (T820), also available from GENETRONICS, INC., can be used.
Square wave electroporation systems deliver controlled electric pulses that rise quickly to a set voltage, stay at that level for a set length of time (pulse length), and then quickly drop to zero. This type of system yields better transformation efficiency for the electroporation of plant protoplast and mammalian cell lines than an exponential decay system.
The ElectroSquarePorator (T820) is the first commercially available square wave electroporation system capable of generating up to 3000 volts. The pulse length can be adjusted from 5 ,sec to 99 msec. The square wave electroporation pulses have a gentler effect on the cells which results in higher cell viability.
' The T820 ElectroSquarePorator is active in both the High Voltage Mode (HVM) (100-3000 volts) and the Low Voltage Mode (LVM)(SO-500 volts). The pulse length for LVM is about 0.3 to 99 msec and for HVM, 5 to 99 ~csec. The T820 has multiple pulsing capability from about 1 to 99 pulses.
Mir and others have used square wave pulses for electrochemotherapy, which allows the insertion of chemotherapeutic agents into cancerous tumors. Mice were _ injected with a low dose of bleomycin. The cancerous tumors were then electroporated resulting in the reduction or complete remission of the tumors (Mir, L.M., Eur. J.
Cancer 27( 1 ):68, 1991 ) .
Saunders has compared the square wave with exponential decay pulses in the electroporation of plant protoplast. Square wave electroporation produced higher transformation efficiency than the exponential decay pulses. He also reported that the optimization of electroporation parameters is much easier with square wave pulses since sufficient transformation efficiency can be produced over a larger range of voltages (Saunders, Guide to Electroporation and Electrofusion, pp.227-247, 1991).
The therapeutic method of the invention includes electrotherapy, also referred to herein as electroporation-mediated therapy, using the apparatus of the invention for the delivery of macromolecules to a cell or tissue. As described earlier, the term "macromolecule" or "molecule" as used herein refers to drugs (e.g., chemotherapeutic agents), nucleic acids (e.g., polynucleotides), peptides and polypeptides, including antibodies. The term polynucleotides include DNA, cDNA and RNA sequences.
Drugs contemplated for use in the method of the invention are typically chemotherapeutic agents having an antitumor or cytotoxic effect. Such drugs or agents include bleomycin, neocarcinostatin, suramin, and cisplatin. Other chemotherapeutic agents will be known to those of skill in the art (see for example The Merck Index). The chemical composition of the agent will dictate the most appropriate time to administer the agent in relation to the administration of the electric pulse. For example, while not wanting to be bound by a particular theory, it is believed that a drug having a low isoelectric point (e.g., neocarcinostatin, IEP=3.78), would likely be more effective if administered post-electroporation in order to avoid electrostatic interaction of the highly charged drug within the field. Further, such drugs as bleomycin, which have a very ' negative log P, (P being the partition coefficient between octanol and water), are very large in size (MW--1400), and are hydrophilic, thereby associating closely with the lipid membrane, diffuse very slowly into a tumor cell and are typically administered prior to or substantially simultaneous with the electric pulse. Electroporation facilitates entry of bleomycin or other similar drugs into the tumor cell by creating pores in the cell membrane.
It may be desirable to modulate the expression of a gene in a cell by the introduction of a molecule by the method of the invention. The term "modulate"
envisions the suppression of expression of a gene when it is over-expressed, or augmentation of expression when it is under-expressed. Where a cell proliferative disorder is associated with the expression of a gene, nucleic acid sequences that interfere with the gene's expression at the translational level can be used. This approach utilizes, for example, antisense nucleic acid, ribozymes, or triplex agents to block transcription or translation of a specific mRNA, either by masking that mRNA with an antisense nucleic acid or triplex agent, or by cleaving it with a ribozyme.
Antisense nucleic acids are DNA or RNA molecules that are complementary to at least a portion of a specific mRNA molecule (Weintraub, Scientific American, 262:40, 1990). In the cell, the antisense nucleic acids hybridize to the corresponding mRNA, forming a double-stranded molecule. The antisense nucleic acids interfere with the translation of the mRNA, since the cell will not translate a mRNA that is double-stranded. Antisense oligomers of about 15 nucleotides are preferred, since they are easily synthesized and are less likely to cause problems than larger molecules when introduced into the target cell. The use of antisense methods to inhibit the in vitro translation of genes is well known in the art (Marcus-Sakura, Anal.Biochem., 172:289, 1988).
Use of an oligonucleotide to stall transcription is known as the triplex strategy since the oligomer winds around double-helical DNA, forming a three-strand helix.
Therefore, these triplex compounds can be designed to recognize a unique site on a - chosen gene (Maher, et al., Antisense Res. and Dev., 1 3 :227, 1991; Helene, C., Anticancer Drug Design, 6 6 :569, 1991 ).
Ribozymes are RNA molecules possessing the ability to specifically cleave other single-stranded RNA in a manner analogous to DNA restriction endonucleases.
Through the modification of nucleotide sequences which encode these RNAs, it is possible to engineer molecules that recognize specific nucleotide sequences in an RNA
molecule and cleave it (Cech, J.Amer.Med. Assn., 260:3030, 1988). A major advantage of this .
approach is that, because they are sequence-specific, only mRNAs with particular sequences are inactivated.
There are two basic types of ribozymes namely, tetrahymena-type (Hasselhoff, Nature, 334:585, 1988) and "hammerhead"-type. Tetrahymena-type ribozymes recognize sequences which are four bases in length, while "hammerhead"-type ribozymes recognize base sequences 11-18 bases in length. The longer the recognition sequence, the greater the likelihood that the sequence will occur exclusively in the target mRNA
species.
Consequently, hammerhead-type ribozymes are preferable to tetrahymena-type ribozymes for inactivating a specific mRNA species and 18-based recognition sequences are preferable to shorter recognition sequences.
The present invention also provides gene therapy for the treatment of cell proliferative or immunologic disorders mediated by a particular gene or absence thereof.
Such therapy would achieve its therapeutic effect by introduction of a specific sense or antisense polynucleotide into cells having the disorder. Delivery of polynucleotides can be achieved using a recombinant expression vector such as a chimeric virus, or the polynucleotide can be delivered as "naked" DNA for example.
Various viral vectors which can be utilized for gene therapy as taught herein include adenovirus, herpes virus, vaccinia, or, preferably, an RNA virus such as a retrovirus. Preferably, the retroviral vector is a derivative of a marine or avian retrovirus. Examples of retroviral vectors in which a single foreign gene can be inserted include, but are not limited to: Moloney marine leukemia virus (MoMuLV), Harvey marine sarcoma virus (HaMuSV), marine mammary tumor virus (MuMTV), and Rous Sarcoma Virus (RSV). When the subject is a human, a vector such as the gibbon ape leukemia virus (GaLV) can be utilized. A number of additional retroviral vectors can incorporate multiple genes. All of these vectors can transfer or incorporate a gene for "
a selectable marker so that transduced cells can be identified and generated.
Therapeutic peptides or polypeptides may also be included in the therapeutic method of the invention. For example, immunomodulatory agents and other biological response modifiers can be administered for incorporation by a cell. The term "biological response modifiers" is meant to encompass substances which are involved in modifying the immune response. Examples of immune response modifiers include such compounds as lymphokines. Lymphokines include tumor necrosis factor, interleukins 1, 2, and 3, lymphotoxin, macrophage activating factor, migration inhibition factor, colony stimulating factor, and alpha-interferon, beta-interferon, and gamma-interferon and their subtypes.
Also included are polynucleotides which encode metabolic enzymes and proteins, including antiangiogenesis compounds, e.g., Factor VIII or Factor IX.
The macromolecule of the invention also includes antibody molecules. The term "antibody" as used herein is meant to include intact molecules as well as fragments thereof, such as Fab and F(ab')Z.
Administration of a drug, polynucleotide or polypeptide, in the method of the invention can be, for example, parenterally by injection, rapid infusion, nasopharyngeal absorption, dermal absorption, and orally. In the case of a tumor, for example, a chemotherapeutic or other agent can be administered locally, systemically or directly injected into the tumor. When a drug, for example, is administered directly into the tumor, it is advantageous to inject the drug in a "fanning" manner. The term "fanning"
refers to administering the drug by changing the direction of the needle as the drug is being inj ected or by multiple inj ections in multiple directions like opening up of a hand fan, rather than as a bolus, in order to provide a greater distribution of drug throughout the tumor. As compared with a volume that is typically used in the art, it is desirable to increase the volume of the drug-containing solution, when the drug is administered (e.g., injected) intratumorally, in order to insure adequate distribution of the drug throughout the tumor. For example, in the EXAMPLES herein, one of skill in the art typically injects 50 p,l of drug-containing solution, however, the results are greatly improved by increasing the volume to 150 ~.1. Preferably, the injection should be done ~ very slowly and at the periphery rather than at the center of the tumor where the intertidal pressure is very high ' Preferably, the molecule is administered substantially contemporaneously with the electroporation treatment. The term "substantially contemporaneously"
means that the molecule and the electroporation treatment are administered reasonably close together with respect to time. The administration of the molecule or therapeutic agent can at any interval, depending upon such factors, for example, as the nature of the tumor, the condition of the patient, the size and chemical characteristics of the molecule and half life of the molecule.
Preparations for parenteral administration include sterile or aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Carriers for occlusive dressings can be used to increase skin permeability and enhance antigen absorption. Liquid dosage forms for oral administration may generally comprise a liposome solution containing the liquid dosage form. Suitable forms for suspending the liposomes include emulsions, suspensions, solutions, syrups, and elixirs containing inert diluents commonly used in the art, such as purified water. Besides the inert diluents, such compositions can also include adjuvants, wetting agents, emulsifying and suspending agents. Further, vasoconstrictor agents can be used to keep the therapeutic agent localized prior to pulsing.
Any cell can be treated by the method of the invention. The illustrative examples provided herein demonstrate the use of the method of the invention for the treatment of tumor cells, e.g., pancreas and lung. Other cell proliferative disorders are amenable to treatment by the electroporation method of the invention. The term "cell proliferative disorder" denotes malignant as well as non-malignant cell populations which often appear to differ from the surrounding tissue both morphologically and genotypically.
Malignant cells (i. e., tumors or cancer) develop as a result of a multi-step process. The method of the invention is useful in treating malignancies or other disorders of the various organ systems, particularly, for example, cells in the pancreas and lung, and also including cells of heart, kidney, muscle, breast, colon, prostate, thymus, testis, and ovary. Preferably the subject is human.
The following examples are intended to illustrate but not limit the invention.
While they are typical of those that might be used, other procedures known to those skilled in the art may alternatively be used.
EXAMPLES
The following examples illustrate the use of electrochemotherapy (ECT) of a poorly differentiated human pancreatic tumor (Panc-3) xenografted subcutaneously on the left flank of nude mice. The single treatment procedure involved injection of bleomycin (0.5 units in 0.15 ml saline) intratumorally, using fanning, as described herein followed by application of six square wave electrical pulses, ten minutes later, using proprietary needle array electrodes arranged along the circumference of a circle 1 cm in diameter. Needle array of variable diameters (e.g., 0.5 cm, 0.75 cm and 1.5 cm can also be used to accommodate tumors of various sizes. Stoppers of various heights can be inserted at the center of the array to make the penetration depth of the needles into the tumor variable. A built-in mechanism allowed switching of electrodes for maximum coverage of the tumor by the pulsed field. The electrical parameters were:
1300 V/cm and 6 x 99 ~.s pulses spaced at 1 sec interval.
Results showed severe necrosis and edema in nearly all the mice at the treatment 1 G ~;+o ~IT4,;lo +l.,o..o .~ ~..1.~+.,.,+:..1 ..,.".1....+:..... :... +t,..
+.-.r..- ....~._~_ i_~__ _ _m-L~ :~
1J J1W. vvaum. uram vva~ a JuuJ1.a11ua1 lcuuGL1V11 111 utc L11111V1 VV111111C
~4.1LCI~ 'd Sll~IlL lIlltlW1 increase due to edema) of the mice in the treated group (D+E+; D=Drug, E=Electrical field), those in the control group (D+E-) increased dramatically. Nearly complete tumor regression was observed in 90% of the mice treated by ECT after 28 days. No response was seen in 10% of the mice. A complete regression with no palpable tumor has been observed in 60% of the cases 77 days after the initial treatment. However, there was tumor regrowth in 20% of the mice 35 days after treatment but at a much slower growth rate compared to the control. This observation has been linked to incomplete treatment of large primary tumors where the needle depth was lower than the Z dimension of the tumor. Histological analysis of tumor samples showed necrotic tumor cell ghosts in D+E+ group compared to a mixture of viable and necrotic cells in D+E- group.
Preliminary studies with human non-small cell lung cancer (NSCLC) tumors xenografted onto nude mice have also shown very encouraging results with ECT treatment with bleomycin.
Example 1:
The tumor cell line Panc-3, a poorly differentiated adenocarcinoma cell line of the pancreas, was supplied by Anticancer, Inc., San Diego. For ECT
experiments, tissue taken from the stock mice, where the tumor line was maintained, was thawed and cut into very small pieces about 1 mm each, and 8-10 pieces were surgically xenografted in a subcutaneous sac made in left flank of nude mice, and then closed with 6.0 surgical suture. After the average tumor size reached about 5 mm, mice with palpable tumors were divided randomly, 10 mice for control group (D+E-; D=Drug, E=Electric field) and mice for ECT treatment, namely bleomycin injection followed by pulsing (D+E+) 10 from a BTX Square Wave T820 Generator. The tumor dimensions were measured and the tumor volume calculated using the formula:
(II/6)xaxbxc where a, b, and c are, respectively, the length, width and thickness of the tumor. 0.5 units Bleomycin (Sigma Chemicals) was dissolved in 0.15 ml of 0.9% NaCl and was injected in each mice intratumorally by fanning for both the control (D+E-) and the treated (D+E+) groups. Ten minutes after the injection, each mouse in the D+E+
group was pulsed from a BTX T820 square wave electroporator with a set of needle array electrodes as described in the present invention. Electrical parameters used were as follows: field strength 1300 V/cm, 6 pulses of 99 ~s each, at 1 sec interval.
The mice were monitored every day for mortality and any signs of a diseased state were noted. The tumor dimensions were measured at regular intervals and tumor growth regression/progression monitored. Another set of nude mice with xenografts of non-small cell lung cancer line was also treated by the same procedure as for the Panc-3 tumors.
Figures l0a and l Ob show the analysis of the tumor volume determined over a 43 day period after ECT using bleomycin for the Panc-3 tumors. There was a dramatic difference between the untreated and treated mice in terms of tumor volume.
There was essentially no detectable tumor after approximately 24 days of treatment. The results of Figure 10 are also summarized in Table 1 below. An illustration of the actual regression of the tumor is shown in Figure 11.
Days after Tumor volume Tumor volume Tumor volume Tumor volume - treatment (mm' ) C1 (mm3) C2 (mm3) Tl (mm3) T2 0 138.746 148.94 123.11 178.37 1 206.979 179.82 210.95 252.72 8 394.786 451.787 104.55 211.11 557.349 798.919 113.21 226.966 18 939.582 881.752 161.73 246.91 10 24 1391.057 1406.98 41.56 47.2228 28 1628.631 1474.21 0 0 35 2619.765 2330.31 0 0 38 2908.912 2333.967 0 0 43 3708.571 5381.759 0 0 15 Cell Line: poorly differentiated human pancreatic tumor (panc3) Mouse model: nude mouse Transplant: subcutaneous xenograft Control mice: C1 and C2 Treated mice: T1 and T2 The Panc-3 experiment was repeated using a non-small cell lung cancer cell line (NSCLC), 177 (Anticancer, San Diego, CA). The results were similar to that found with bleomycin and Panc-3 as shown in Figures 12a and 12b. In one experiment, a tumor that had recurred was retreated at day 27 (Figure 13) and after 7 days, there was no evidence of tumor.
The Panc-3 and NSCLC models were utilized with the drug neocarcinostatin ' (NCS) following the same procedures as outlined above. As shown in Figure 14a and 14b, pre-pulse dosing with NCS in a manner similar to that used for the bleomycin studies, was not effective in reducing tumor size at all. It was believed that due to the low isoelectric point of NCS, electrostatic interaction prevented the drug from entering the tumor cell. Therefore, the experiment was repeated by pulsing first and inj ecting NCS post-pulse (pp).
Figure 14c shows the initial tumor volume (I) as compared to the final tumor volume (F) at day 13 for 7 mice treated (Mouse ID 1-7). In several of the mice (ID 1, 2, 4, and 7), an increase in tumor volume was observed, but appeared to be due to edema. However, as shown in Figure 14d, when a separate group of 5 mice were examined at day 23, all mice showed a marked reduction in tumor volume.
A comparison of Figures 14 a and b with 14 c and d indicated that post-pulse with NCS was more effective than pre-pulse administration for NCS.
Summary The present Examples illustrate that a poorly differentiated Pancreatic cancer (Panc-3) and Non-srriall cell lung cancer (NSCLC) xenografted subcutaneously onto nude mice can be effectively treated by the electrochemotherapy protocol using bleomycin or NCS and needle array electrodes. Other similar chemotherapeutic agents can also be effective using the method of the invention.
The results show a complete regression of Panc-3 tumors was achieved in 60%
of the treated group with no palpable tumor seen even 77 days after the single treatment.
Partial regression (80% reduction in tumor volume) was observed in 30% of cases, while only 10% did not respond (Table 2).
Histological studies clearly showed severe necrosis of the tumor region for the group subjected to ECT whereas no necrosis was apparent in the control group.
Intratumoral drug injection with larger volume of bleomycin, combined with fanning to maximize uniform drug distribution throughout the tumor volume, was found to be very effective as compared to the conventional mode of injecting the drug prior to pulsing.
Electrochemotherapy of Panc-3 with Bleomvcin Days after 28 35 57 77 treatment CR (100%) 6 6 6 6 PR (80%) 3 NR (%) 1 1 1 1 Death 2*
Tumor regrowth 2 Retreatment 2 Histology 1 Number of mice treated: 10 CR: Complete Regression PR: Partial Regression NR: No Response * 1 mice died after retreatment 1 mice died after 64 days survival Although the invention has been described with reference to the presently preferred embodiment, it should be understood that various modifications can be made without departing from the spirit of the invention: Accordingly, the invention is limited only by the following claims.
Accordingly, it is a primary object of the present invention to provide an improved apparatus that can be conveniently and effectively positioned to generate ' predetermined electric fields in pre-selected tissue.
It is another principal object of the present invention to provide an improved a apparatus that provides an effective and convenient means for positioning electrodes into tissue for the injection of therapeutic compounds into the tissue and application of electric fields to the tissue.
In accordance with a primary aspect of the present invention an electrode apparatus for the application of electroporation to a portion of the body of a patient, comprises a support member, an array of a plurality of opposed pairs of needle electrodes adjustably mounted on the support member for insertion into tissue at selected positions and distances from one another, and means including a signal generator and switch means for applying an electric signal to selected pairs of the electrodes for 1 ~ generating an electric field of a predetermined strength.
Another aspect of the invention includes needles that function for injection of therapeutic substances into tissue and function as electrodes for generating electric fields for portion of cells of the tissue.
In yet another aspect of the invention is provided a therapeutic method utilizing the needle array apparatus for the treatment of cells, particularly tumor cells.
BRIEF DESCRIPTION OF DRAWING
The objects, advantages and features of this invention will be more readily appreciated from the following detailed description, when read in conjunction with the accompanying drawing, in which:
Fig. 1 is a side elevation view, in section of a needle assembly in accordance with a preferred embodiment of the invention.
Fig. 2 is a bottom view of the embodiment of Fig. 1.
Fig. 3 is an assembly drawing showing a perspective view of an alternate embodiment of the invention .
~~T
yy y'.
Fig. 4 is a perspective view of the embodiment of Fig. 3 shown assembled.
Fig. 5 is a perspective view of a selector switch for the electrode assembly of Fig.4.
Figs. 6a-6c is a diagrammatic illustration of selected contact positions of the switch of Fig. 5.
Fig. 7 is a perspective view of a further embodiment of the invention.
Fig. 8 is a perspective view of a still further embodiment of the invention.
Figs. 9a-9d is a top plan view, illustrating a preferred form of electrodes and sequence of use.
Figs. l0a and l Ob show the tumor volume after 43 days of ECT with bleomycin in Panc-3 xenografted nude mice. (D=drug; E=electroporation) Fig. 11 is an illustration of tumor growth of Panc-3 cells after ECT with bleomycin in nude mice.
Figs. 12a and 12b show the tumor volume after 20 and 34 days of ECT with 1 S bleomycin, respectively, in non-small cell lung carcinoma (NSCLC) xenografted nude mice. (D=drug; E=electroporation) Fig. 13 shows the tumor volume after 34 days of ECT with bleomycin in non-small cell lung carcinoma (NSCLC) xenografted nude mice. The arrow indicates retreatment of one mouse at day 27. (D=drug; E=electroporation) Figs. 14a and 14b show pre-pulse dosing with neocarcinostatin in Panc-3 and NSCLC, respectively, in the nude mouse model.
Figs. 14c and 14d show post-pulse dosing with neocarcinostatin in Panc-3 in the nude mouse model.
BEST MODE FOR CARRYING OUT THE INVENTION
As used herein the term "molecules" includes pharmacological agents, genes, antibodies or other proteins. One human therapeutic application of electroporation consists of infusion of an anticancer drug and electroporation of the drug into the tumor by applying voltage pulses between electrodes disposed on opposite sides of the tumor, called electrochemotherapy (ECT). The present invention was devised primarily for enabling ECT such as that reported by Okino and Mir et al to be carried out on non-?; CA 02218255 1997-10-14 :~.WP60'.USERS\TEMP.'.PATENTS~f'CT'GENESS.ftPL FZEPLACLl'VI~S1~IT SHEET
surface tumors such as those inside the body. However, it may be utilized for other therapeutic applications.
Referring to Fig. 1 of the drawings, a needle assembly for illustrative purposes is illustrated and designated generally by the numeral 10. The needle assembly comprises an elongated tubular support body 12 which is preferably in the form of a hollow stainless steel shaft. A center needle mount 14 is mounted on the lower end of the shaft 12 and has a central bore 16 for receiving and guiding a center needle 18. The shaft 12 includes a needle exit slot 20 through which the needle electrode 18 extends from the interior thereof to the exterior where it is secured by a clamp 22 to the outside of the tube 12.
The upper end of the electrode 18 may be secured to a screw 24 for connection to an electrical circuit. The lower end of the tubular holder 12 includes threats 26 for threatably receiving a collar 28 for mounting a plurality of needles and a stop collar 30 for stopping or locking the collar 28 in position.
A plurality of needles 32 are mounted in grooves 3~. equally spaced around the outer surface of the needle collar 28. This provides a circular array of equally spaced needles, eight in number in the illustrated embodiment. The needles are held in place by a band clamp 36, having the ends clamped together by a screw or nut and bolt 38 which also serves as an electrical connection for the needles. The band clamp directly engages and holds the needles in place.
This electrode assembly is designed to apply electrical energy to living tissue when the needles are inserted into the tissue. The center needle 18 acts as one electrode, such as an anode or cathode, and the other or annular arrangement of needles functions as the opposite electrode. All of these needles are held in fixed positions when the clamps are installed and secured. One or more of the needles may be cannular or tubular in form for injecting molecules of genes, pharmaceutical or other substances into the tissue.
In one mode of operation the center needle should be adjusted in order to achieve the desired tissue penetration. This is done by releasing the pressure of the center needle 30- clamp 22 and sliding the center needle 18 outwardly or inwardly, as seen in Fig. 1, so that it extends from the center needle guide 14 to desired penetration distance. The u;~ ~' F:\WP60\USERS\1'EMP2\PATENTS\I'C11GENESS,RPL REPLACEMENT SHEET
needle is then clamped in position. Thereafter the annular needles 32 are adjusted to achieve the desired penetration into the tissue. This can be accomplished by releasing the pressure of the band clamp 36 and sliding the needles 32 into the desired position.
Minor adjustments can also be made by moving the needle collar 28 toward and away from the end of the shaft 12. A therapeutic substance may be injected into the tissue through one or more of these needles or by a separate means.
After all needles are adjusted to the proper penetration, the shaft 12 is grasped and the needles are inserted into the tissue to the desired depth. Thereafter, a suitable pulse generator is connected to the electrode assembly and the appropriate voltage applied to the electrodes. A suitable quantity of therapeutic substance such as genes or molecules of a suitable chemical or pharmaceutical for treatment of the tissue is injected into the tissue before the voltage is applied.
A modification to this electrode assembly could include a solid non-penetrating electrode (not shown) in place of the center needle. The non-penetrating center electrode could be any suitable shape conductor such as a button or plate attached to the end of the shaft 12 to contact the surface tissue. The annular needle arrangement would be adjusted to penetrate the tissue at the desired depth when the center electrode is resting on a tissue surface. Electrical energy would flow from the penetrating needles through the tissue and to the central electrode on the surface. These arrangements can be utilized to treat near surface tumors where the circular array of electrodes are designed to encircle the tumor. The central electrode is positioned such that the electrical energy flows through the tumor to the central electrode.
Other advantages of this electrode assembly are that all needles 18 and 32 can be independently adjusted to achieve the desired penetration. The needle 28 collar can also be adjusted to position it from the end of the shaft 12 so that insertion of the center and annular needles can be directly observed. In addition, the needle collar 28 can have any size or configuration to encircle the tissue area to be treated. The needles can also be energized in pairs as described relative to Figs. 3-6.
Referring to Figs. 3 and 4 an alternate embodiment of a circular array needle electrode assembly is illustrated and designated generally by the numeral 40.
This needle assembly comprises a circular array of needles 42 through 52, which are mounted in equally spaced relation in a hub 54 mounted on an elongated cylindrical shaft 56.
~.;, _'7_ The hub 54 is preferably of a suitably selected diameter to provide the desired diameter of the arrays to position around a tumor or other tissue to be treated. One or more of the needles may be hollow to enable the injection of molecules of a therapeutic a substance, as will be more fully described hereinafter.
An electrical connector socket assembly comprises a body member 58 having a central opening or bore 60 for receipt of shaft 56 and an annular array of a plurality of sockets 62 through 72 for receipt of the ends of needles 42 through 52. The sockets 62 through 72 electrically connect the needles to leads 74 through 84 which connect to a distributing switch, as will be subsequently described.
The electrical connector socket 58 fits onto shaft 56 with the end of the needles extending into the electrical sockets 62 through 72 for connecting to the leads 74 through 84. The shaft 56 which mounts the needle array hub 54 and the socket assembly 58 mounts onto a holder 86 adapted to be held in the hand. The holder 86 has an elongated cylindrical configuration adapted to be held in the hand for manipulation.
The holder 86 has a forward socket and including a forwardly extending tubular shaft 88 having a bore 90 into which shaft 56 extends while the shaft 88 extends into a bore (not shown) within the connector member 58. The shaft 56 extends into bore 90 and has a annular groove or recess 92 which is engaged by a retainer latch which comprises a transverse plug 94 in a bore 96 biased to one side and including a bore 98 in which the annular slot 92 extends and is retained in the holder. A spring 102 mounted in bore 96 biases plug 94 to the latched position. The shaft 56 may be released for removal by pressing on end 100 of plug 94.
The holder when assembled as shown in Fig. 4 may be grasped in the hand and the needles inserted into a selected tissue area. The needles 42-52 are preferably spaced and positioned to surround the selected tissue of treatment. One or more of the needles 42-52, as previously explained, may be hollow to enable the injection of the desired ~ therapeutic substance. The electrode leads 74-84 are then connected in a preferred arrangement to a rotatable switch assembly, as shown in Fig. 5, which enables the selection of opposed pairs of the needles for activation or the application of the electrical potential.
_g_ The switch assembly designated generally by the numeral 104 comprises a stationary housing 106 which, in the illustrated embodiment, is generally cylindrical in configuration and in which is mounted a rotor 108 with spaced contacts 110 and connected by a pair of conductors 114 and 116 to a pulse power generator 115.
The rotor contacts l 10 and 112 are positioned within housing 106 to engage annular contacts 118, 120, 122, 124, 126 and 128 to which leads 74-84 are connected.
Referring to Figs. 6a, b and c, the rotor 108 has an internal portion having contacts 110 and 112 each of which bridge between two contacts 118-128 to which the leads 74 through 84 are connected to connect the source of power. The internal contacts 110 and 112 rotate with the rotor 108 and can be selectively positioned in conductive relation with pairs of the internal contacts 118-128 to thereby activate opposed pairs of the needle electrodes. This enables the operator to selectively position the electrodes surrounding a selected tissue and to selectively apply the direction of the electrical field as desired for optimum treatment. The rotor 108 enables the field to be selectively generated around or across the tissue from all directions.
Referring to Fig. 7 an alternate embodiment of an electric field generating array of parallel adjustably positionable electrodes, as disclosed in the parent application, is illustrated. The electrode assembly designated generally by the numeral 130 includes a pair of spaced apart arrays 132 and 134 of conductive needle electrodes 136 and 138 mounted on a dielectric carrier or support member 140. The needle array 132 is held in a fixed clamp 142 which allows the needles 136 to be adjusted in depth relative to the support 140.
The needles 138 are mounted in a moveable clamp 146 which is adjustably mounted on support member 140 by a clamp screw 148. The needles 136 and 138 are each provided with a penetration stop 144. The gap spacing clamp screw 148 secures the clamp 146 in selected positions on the support 140. A gap spacing sensor senses the distance between the needle arrays 132 and 134 and generates a signal that is sent to the pulse generator via conductor cable 152. A pulse generator is connected to the needle electrodes by means of cables 154 and 156. ' Referring to Fig. 8, details of a needle holder or template for various arrangements for establishing a spaced pair or parallel arrays of needles is illustrated.
This embodiment comprises a base holder member 158 having a plurality of adjacently positioned parallel slots 160 into which selected needles 162 and 164 may be positioned in selected spaced relation. This holder may serve to mount a pair of oppositely " polarized needle electrodes 162 and 164, as illustrated. These can be selectively positioned in selected space relationship to be disposed on opposite sides of a selected tissue. The needles are clamped into the slots by a clamp or plate 159. In addition, the holder may be used in combination with an additional holder for provision of multiple arrays on opposite sides of a selected tissue. The illustrated needles may be connected by conductors 166 and 168 to a suitable pulse generator.
Referring to Figs. 9a through 9d, an additional aspect of the invention is illustrated. As more clearly illustrated, the combination electrodes may take the form of separate needles 170 and 172 which may be first inserted into or beside a selected tissue area such as on opposite sides of a tumor 194 as illustrated.
Thereafter the needles may be connected to a syringe or other source of molecules and used to inject a selected molecular solution into the tissue area. The needles may be non-conductive and a pair of electrodes 176 and 178, as illustrated in Fig. 9b, are selectively fed through the bore or lumen of the respective needles into the tissue, as illustrated, and thereafter the needle is removed, as shown in Fig. 9c. The electrodes 176 and 178 are each provided with an elongated insulated conductor 180 and 182 with conductive tips 184 and 186.
A pair of conductors 188 and 190 from a suitable power generator may then be connected to the ends of the conductors of the electrodes by micro clamps 192 and 194, as shown in 9d, and an electric potential applied across the electrodes. This generates a field in the tissue and electroporates the cells of the selected tissue, such as a tumor or the like. This electroporation enables the selected molecules to enter the cells of the tissue and more efficiently kill or alter the cells as desired. This form of needle and electrode may be used with any or all the above described assemblies.
These needle electrode assemblies, as above described, enable the in vivo " positioning of electrodes in or adjacent to subsurface tumors or other tissue. While the focus of the present application has been on electrochemotherapy, the embodiment of the subject invention may be applied to other treatments, such as gene therapy of certain organs of the body.
The nature of the electric field to be generated is determined by the nature of the tissue, the size of the selected tissue and its location. It is desirable that the field be as homogenous as possible and of the correct amplitude. Excessive field strength results in lysing of cells, whereas a low field strength results in reduced efficacy.
The electrodes may be mounted and manipulated in many ways including but not limited to those in the parent application. The electrodes may be conveniently manipulated on and by forceps to internal position.
The waveform of the electrical signal provided by the pulse generator can be an exponentially decaying pulse, a square pulse, a unipolar oscillating pulse train or a bipolar oscillating pulse train. The electric field strength can be 0.2kV/cm to 20kV/cm.
The pulse length can be ten ~,s to 100 ms. There can be one to one hundred pulses. Of course, the waveform, electric field strength and pulse duration are also dependent upon the type of cells and the type of molecules that are to enter the cells via electroporation.
The various parameters including electric field strengths required for the electroporation of any known cell is generally available from the many research papers reporting on the subject, as well as from a database maintained by Genetronics, Inc., San Diego, California, assignee of the subject application. The electric fields needed for in vivo cell electroporation, such as ECT, are similar in amplitude to the fields required for cells in vitro. These are in the range of from 100 V/cm to several kV/cm. This has been verified by the inventors own experiments and those of others reported in scientific publications. The first in vivo application of pulsed electric fields in the chemotherapy field to treat tumors was reported in 1987 by Okino in Japan.
Pulse generators for carrying out the procedures described herein are and have been available on the market for a number of years. One suitable signal generator is the ELECTRO CELL MANIPULATOR Model ECM 600 commercially available from GENETRONICS, INC. of San Diego, California, U.S.A. The ECM 600 signal generator generates a pulse from the complete discharge of a capacitor which results in an exponentially decaying waveform. The electric signal generated by this signal generator is characterized by a fast rise time and an exponential tail. In the signal generator, the electroporation pulse length is set by selecting one of ten timing resistors marked R1 through R10. They are active in both High Voltage Mode (HVM) (capacitance fixed at fifty microfarads) and Low Voltage Mode (LVM) (with a capacitance range from 25 to 3,175 microfarads).
The ECM 600 signal generator has a control knob that permits the adjustment of the amplitude of the set charging voltage applied to the internal capacitors from 50 to 500 volts in LVM and from 0.05 to 2.SkV in the HVM. The amplitude of the electrical signal is shown on a display incorporated into the ECM 600 signal generator.
This device further includes a plurality of push button switches for controlling pulse length, in the Low VM mode, by a simultaneous combination of resistors parallel to the output and a bank of seven selectable additive capacitors.
The ECM 600 signal generator also includes a single automatic charge and pulse push button. This button may be depressed to initiate both charging of the internal capacitors to the set voltage and to deliver a pulse to the outside electrodes in an automatic cycle that takes less than five seconds. The manual button may be sequentially pressed to repeatedly apply the predetermined electric field.
Preferably, the therapeutic method of the invention utilizes a square wave pulse electroporation system. For example, the ElectroSquarePorator (T820), also available from GENETRONICS, INC., can be used.
Square wave electroporation systems deliver controlled electric pulses that rise quickly to a set voltage, stay at that level for a set length of time (pulse length), and then quickly drop to zero. This type of system yields better transformation efficiency for the electroporation of plant protoplast and mammalian cell lines than an exponential decay system.
The ElectroSquarePorator (T820) is the first commercially available square wave electroporation system capable of generating up to 3000 volts. The pulse length can be adjusted from 5 ,sec to 99 msec. The square wave electroporation pulses have a gentler effect on the cells which results in higher cell viability.
' The T820 ElectroSquarePorator is active in both the High Voltage Mode (HVM) (100-3000 volts) and the Low Voltage Mode (LVM)(SO-500 volts). The pulse length for LVM is about 0.3 to 99 msec and for HVM, 5 to 99 ~csec. The T820 has multiple pulsing capability from about 1 to 99 pulses.
Mir and others have used square wave pulses for electrochemotherapy, which allows the insertion of chemotherapeutic agents into cancerous tumors. Mice were _ injected with a low dose of bleomycin. The cancerous tumors were then electroporated resulting in the reduction or complete remission of the tumors (Mir, L.M., Eur. J.
Cancer 27( 1 ):68, 1991 ) .
Saunders has compared the square wave with exponential decay pulses in the electroporation of plant protoplast. Square wave electroporation produced higher transformation efficiency than the exponential decay pulses. He also reported that the optimization of electroporation parameters is much easier with square wave pulses since sufficient transformation efficiency can be produced over a larger range of voltages (Saunders, Guide to Electroporation and Electrofusion, pp.227-247, 1991).
The therapeutic method of the invention includes electrotherapy, also referred to herein as electroporation-mediated therapy, using the apparatus of the invention for the delivery of macromolecules to a cell or tissue. As described earlier, the term "macromolecule" or "molecule" as used herein refers to drugs (e.g., chemotherapeutic agents), nucleic acids (e.g., polynucleotides), peptides and polypeptides, including antibodies. The term polynucleotides include DNA, cDNA and RNA sequences.
Drugs contemplated for use in the method of the invention are typically chemotherapeutic agents having an antitumor or cytotoxic effect. Such drugs or agents include bleomycin, neocarcinostatin, suramin, and cisplatin. Other chemotherapeutic agents will be known to those of skill in the art (see for example The Merck Index). The chemical composition of the agent will dictate the most appropriate time to administer the agent in relation to the administration of the electric pulse. For example, while not wanting to be bound by a particular theory, it is believed that a drug having a low isoelectric point (e.g., neocarcinostatin, IEP=3.78), would likely be more effective if administered post-electroporation in order to avoid electrostatic interaction of the highly charged drug within the field. Further, such drugs as bleomycin, which have a very ' negative log P, (P being the partition coefficient between octanol and water), are very large in size (MW--1400), and are hydrophilic, thereby associating closely with the lipid membrane, diffuse very slowly into a tumor cell and are typically administered prior to or substantially simultaneous with the electric pulse. Electroporation facilitates entry of bleomycin or other similar drugs into the tumor cell by creating pores in the cell membrane.
It may be desirable to modulate the expression of a gene in a cell by the introduction of a molecule by the method of the invention. The term "modulate"
envisions the suppression of expression of a gene when it is over-expressed, or augmentation of expression when it is under-expressed. Where a cell proliferative disorder is associated with the expression of a gene, nucleic acid sequences that interfere with the gene's expression at the translational level can be used. This approach utilizes, for example, antisense nucleic acid, ribozymes, or triplex agents to block transcription or translation of a specific mRNA, either by masking that mRNA with an antisense nucleic acid or triplex agent, or by cleaving it with a ribozyme.
Antisense nucleic acids are DNA or RNA molecules that are complementary to at least a portion of a specific mRNA molecule (Weintraub, Scientific American, 262:40, 1990). In the cell, the antisense nucleic acids hybridize to the corresponding mRNA, forming a double-stranded molecule. The antisense nucleic acids interfere with the translation of the mRNA, since the cell will not translate a mRNA that is double-stranded. Antisense oligomers of about 15 nucleotides are preferred, since they are easily synthesized and are less likely to cause problems than larger molecules when introduced into the target cell. The use of antisense methods to inhibit the in vitro translation of genes is well known in the art (Marcus-Sakura, Anal.Biochem., 172:289, 1988).
Use of an oligonucleotide to stall transcription is known as the triplex strategy since the oligomer winds around double-helical DNA, forming a three-strand helix.
Therefore, these triplex compounds can be designed to recognize a unique site on a - chosen gene (Maher, et al., Antisense Res. and Dev., 1 3 :227, 1991; Helene, C., Anticancer Drug Design, 6 6 :569, 1991 ).
Ribozymes are RNA molecules possessing the ability to specifically cleave other single-stranded RNA in a manner analogous to DNA restriction endonucleases.
Through the modification of nucleotide sequences which encode these RNAs, it is possible to engineer molecules that recognize specific nucleotide sequences in an RNA
molecule and cleave it (Cech, J.Amer.Med. Assn., 260:3030, 1988). A major advantage of this .
approach is that, because they are sequence-specific, only mRNAs with particular sequences are inactivated.
There are two basic types of ribozymes namely, tetrahymena-type (Hasselhoff, Nature, 334:585, 1988) and "hammerhead"-type. Tetrahymena-type ribozymes recognize sequences which are four bases in length, while "hammerhead"-type ribozymes recognize base sequences 11-18 bases in length. The longer the recognition sequence, the greater the likelihood that the sequence will occur exclusively in the target mRNA
species.
Consequently, hammerhead-type ribozymes are preferable to tetrahymena-type ribozymes for inactivating a specific mRNA species and 18-based recognition sequences are preferable to shorter recognition sequences.
The present invention also provides gene therapy for the treatment of cell proliferative or immunologic disorders mediated by a particular gene or absence thereof.
Such therapy would achieve its therapeutic effect by introduction of a specific sense or antisense polynucleotide into cells having the disorder. Delivery of polynucleotides can be achieved using a recombinant expression vector such as a chimeric virus, or the polynucleotide can be delivered as "naked" DNA for example.
Various viral vectors which can be utilized for gene therapy as taught herein include adenovirus, herpes virus, vaccinia, or, preferably, an RNA virus such as a retrovirus. Preferably, the retroviral vector is a derivative of a marine or avian retrovirus. Examples of retroviral vectors in which a single foreign gene can be inserted include, but are not limited to: Moloney marine leukemia virus (MoMuLV), Harvey marine sarcoma virus (HaMuSV), marine mammary tumor virus (MuMTV), and Rous Sarcoma Virus (RSV). When the subject is a human, a vector such as the gibbon ape leukemia virus (GaLV) can be utilized. A number of additional retroviral vectors can incorporate multiple genes. All of these vectors can transfer or incorporate a gene for "
a selectable marker so that transduced cells can be identified and generated.
Therapeutic peptides or polypeptides may also be included in the therapeutic method of the invention. For example, immunomodulatory agents and other biological response modifiers can be administered for incorporation by a cell. The term "biological response modifiers" is meant to encompass substances which are involved in modifying the immune response. Examples of immune response modifiers include such compounds as lymphokines. Lymphokines include tumor necrosis factor, interleukins 1, 2, and 3, lymphotoxin, macrophage activating factor, migration inhibition factor, colony stimulating factor, and alpha-interferon, beta-interferon, and gamma-interferon and their subtypes.
Also included are polynucleotides which encode metabolic enzymes and proteins, including antiangiogenesis compounds, e.g., Factor VIII or Factor IX.
The macromolecule of the invention also includes antibody molecules. The term "antibody" as used herein is meant to include intact molecules as well as fragments thereof, such as Fab and F(ab')Z.
Administration of a drug, polynucleotide or polypeptide, in the method of the invention can be, for example, parenterally by injection, rapid infusion, nasopharyngeal absorption, dermal absorption, and orally. In the case of a tumor, for example, a chemotherapeutic or other agent can be administered locally, systemically or directly injected into the tumor. When a drug, for example, is administered directly into the tumor, it is advantageous to inject the drug in a "fanning" manner. The term "fanning"
refers to administering the drug by changing the direction of the needle as the drug is being inj ected or by multiple inj ections in multiple directions like opening up of a hand fan, rather than as a bolus, in order to provide a greater distribution of drug throughout the tumor. As compared with a volume that is typically used in the art, it is desirable to increase the volume of the drug-containing solution, when the drug is administered (e.g., injected) intratumorally, in order to insure adequate distribution of the drug throughout the tumor. For example, in the EXAMPLES herein, one of skill in the art typically injects 50 p,l of drug-containing solution, however, the results are greatly improved by increasing the volume to 150 ~.1. Preferably, the injection should be done ~ very slowly and at the periphery rather than at the center of the tumor where the intertidal pressure is very high ' Preferably, the molecule is administered substantially contemporaneously with the electroporation treatment. The term "substantially contemporaneously"
means that the molecule and the electroporation treatment are administered reasonably close together with respect to time. The administration of the molecule or therapeutic agent can at any interval, depending upon such factors, for example, as the nature of the tumor, the condition of the patient, the size and chemical characteristics of the molecule and half life of the molecule.
Preparations for parenteral administration include sterile or aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Carriers for occlusive dressings can be used to increase skin permeability and enhance antigen absorption. Liquid dosage forms for oral administration may generally comprise a liposome solution containing the liquid dosage form. Suitable forms for suspending the liposomes include emulsions, suspensions, solutions, syrups, and elixirs containing inert diluents commonly used in the art, such as purified water. Besides the inert diluents, such compositions can also include adjuvants, wetting agents, emulsifying and suspending agents. Further, vasoconstrictor agents can be used to keep the therapeutic agent localized prior to pulsing.
Any cell can be treated by the method of the invention. The illustrative examples provided herein demonstrate the use of the method of the invention for the treatment of tumor cells, e.g., pancreas and lung. Other cell proliferative disorders are amenable to treatment by the electroporation method of the invention. The term "cell proliferative disorder" denotes malignant as well as non-malignant cell populations which often appear to differ from the surrounding tissue both morphologically and genotypically.
Malignant cells (i. e., tumors or cancer) develop as a result of a multi-step process. The method of the invention is useful in treating malignancies or other disorders of the various organ systems, particularly, for example, cells in the pancreas and lung, and also including cells of heart, kidney, muscle, breast, colon, prostate, thymus, testis, and ovary. Preferably the subject is human.
The following examples are intended to illustrate but not limit the invention.
While they are typical of those that might be used, other procedures known to those skilled in the art may alternatively be used.
EXAMPLES
The following examples illustrate the use of electrochemotherapy (ECT) of a poorly differentiated human pancreatic tumor (Panc-3) xenografted subcutaneously on the left flank of nude mice. The single treatment procedure involved injection of bleomycin (0.5 units in 0.15 ml saline) intratumorally, using fanning, as described herein followed by application of six square wave electrical pulses, ten minutes later, using proprietary needle array electrodes arranged along the circumference of a circle 1 cm in diameter. Needle array of variable diameters (e.g., 0.5 cm, 0.75 cm and 1.5 cm can also be used to accommodate tumors of various sizes. Stoppers of various heights can be inserted at the center of the array to make the penetration depth of the needles into the tumor variable. A built-in mechanism allowed switching of electrodes for maximum coverage of the tumor by the pulsed field. The electrical parameters were:
1300 V/cm and 6 x 99 ~.s pulses spaced at 1 sec interval.
Results showed severe necrosis and edema in nearly all the mice at the treatment 1 G ~;+o ~IT4,;lo +l.,o..o .~ ~..1.~+.,.,+:..1 ..,.".1....+:..... :... +t,..
+.-.r..- ....~._~_ i_~__ _ _m-L~ :~
1J J1W. vvaum. uram vva~ a JuuJ1.a11ua1 lcuuGL1V11 111 utc L11111V1 VV111111C
~4.1LCI~ 'd Sll~IlL lIlltlW1 increase due to edema) of the mice in the treated group (D+E+; D=Drug, E=Electrical field), those in the control group (D+E-) increased dramatically. Nearly complete tumor regression was observed in 90% of the mice treated by ECT after 28 days. No response was seen in 10% of the mice. A complete regression with no palpable tumor has been observed in 60% of the cases 77 days after the initial treatment. However, there was tumor regrowth in 20% of the mice 35 days after treatment but at a much slower growth rate compared to the control. This observation has been linked to incomplete treatment of large primary tumors where the needle depth was lower than the Z dimension of the tumor. Histological analysis of tumor samples showed necrotic tumor cell ghosts in D+E+ group compared to a mixture of viable and necrotic cells in D+E- group.
Preliminary studies with human non-small cell lung cancer (NSCLC) tumors xenografted onto nude mice have also shown very encouraging results with ECT treatment with bleomycin.
Example 1:
The tumor cell line Panc-3, a poorly differentiated adenocarcinoma cell line of the pancreas, was supplied by Anticancer, Inc., San Diego. For ECT
experiments, tissue taken from the stock mice, where the tumor line was maintained, was thawed and cut into very small pieces about 1 mm each, and 8-10 pieces were surgically xenografted in a subcutaneous sac made in left flank of nude mice, and then closed with 6.0 surgical suture. After the average tumor size reached about 5 mm, mice with palpable tumors were divided randomly, 10 mice for control group (D+E-; D=Drug, E=Electric field) and mice for ECT treatment, namely bleomycin injection followed by pulsing (D+E+) 10 from a BTX Square Wave T820 Generator. The tumor dimensions were measured and the tumor volume calculated using the formula:
(II/6)xaxbxc where a, b, and c are, respectively, the length, width and thickness of the tumor. 0.5 units Bleomycin (Sigma Chemicals) was dissolved in 0.15 ml of 0.9% NaCl and was injected in each mice intratumorally by fanning for both the control (D+E-) and the treated (D+E+) groups. Ten minutes after the injection, each mouse in the D+E+
group was pulsed from a BTX T820 square wave electroporator with a set of needle array electrodes as described in the present invention. Electrical parameters used were as follows: field strength 1300 V/cm, 6 pulses of 99 ~s each, at 1 sec interval.
The mice were monitored every day for mortality and any signs of a diseased state were noted. The tumor dimensions were measured at regular intervals and tumor growth regression/progression monitored. Another set of nude mice with xenografts of non-small cell lung cancer line was also treated by the same procedure as for the Panc-3 tumors.
Figures l0a and l Ob show the analysis of the tumor volume determined over a 43 day period after ECT using bleomycin for the Panc-3 tumors. There was a dramatic difference between the untreated and treated mice in terms of tumor volume.
There was essentially no detectable tumor after approximately 24 days of treatment. The results of Figure 10 are also summarized in Table 1 below. An illustration of the actual regression of the tumor is shown in Figure 11.
Days after Tumor volume Tumor volume Tumor volume Tumor volume - treatment (mm' ) C1 (mm3) C2 (mm3) Tl (mm3) T2 0 138.746 148.94 123.11 178.37 1 206.979 179.82 210.95 252.72 8 394.786 451.787 104.55 211.11 557.349 798.919 113.21 226.966 18 939.582 881.752 161.73 246.91 10 24 1391.057 1406.98 41.56 47.2228 28 1628.631 1474.21 0 0 35 2619.765 2330.31 0 0 38 2908.912 2333.967 0 0 43 3708.571 5381.759 0 0 15 Cell Line: poorly differentiated human pancreatic tumor (panc3) Mouse model: nude mouse Transplant: subcutaneous xenograft Control mice: C1 and C2 Treated mice: T1 and T2 The Panc-3 experiment was repeated using a non-small cell lung cancer cell line (NSCLC), 177 (Anticancer, San Diego, CA). The results were similar to that found with bleomycin and Panc-3 as shown in Figures 12a and 12b. In one experiment, a tumor that had recurred was retreated at day 27 (Figure 13) and after 7 days, there was no evidence of tumor.
The Panc-3 and NSCLC models were utilized with the drug neocarcinostatin ' (NCS) following the same procedures as outlined above. As shown in Figure 14a and 14b, pre-pulse dosing with NCS in a manner similar to that used for the bleomycin studies, was not effective in reducing tumor size at all. It was believed that due to the low isoelectric point of NCS, electrostatic interaction prevented the drug from entering the tumor cell. Therefore, the experiment was repeated by pulsing first and inj ecting NCS post-pulse (pp).
Figure 14c shows the initial tumor volume (I) as compared to the final tumor volume (F) at day 13 for 7 mice treated (Mouse ID 1-7). In several of the mice (ID 1, 2, 4, and 7), an increase in tumor volume was observed, but appeared to be due to edema. However, as shown in Figure 14d, when a separate group of 5 mice were examined at day 23, all mice showed a marked reduction in tumor volume.
A comparison of Figures 14 a and b with 14 c and d indicated that post-pulse with NCS was more effective than pre-pulse administration for NCS.
Summary The present Examples illustrate that a poorly differentiated Pancreatic cancer (Panc-3) and Non-srriall cell lung cancer (NSCLC) xenografted subcutaneously onto nude mice can be effectively treated by the electrochemotherapy protocol using bleomycin or NCS and needle array electrodes. Other similar chemotherapeutic agents can also be effective using the method of the invention.
The results show a complete regression of Panc-3 tumors was achieved in 60%
of the treated group with no palpable tumor seen even 77 days after the single treatment.
Partial regression (80% reduction in tumor volume) was observed in 30% of cases, while only 10% did not respond (Table 2).
Histological studies clearly showed severe necrosis of the tumor region for the group subjected to ECT whereas no necrosis was apparent in the control group.
Intratumoral drug injection with larger volume of bleomycin, combined with fanning to maximize uniform drug distribution throughout the tumor volume, was found to be very effective as compared to the conventional mode of injecting the drug prior to pulsing.
Electrochemotherapy of Panc-3 with Bleomvcin Days after 28 35 57 77 treatment CR (100%) 6 6 6 6 PR (80%) 3 NR (%) 1 1 1 1 Death 2*
Tumor regrowth 2 Retreatment 2 Histology 1 Number of mice treated: 10 CR: Complete Regression PR: Partial Regression NR: No Response * 1 mice died after retreatment 1 mice died after 64 days survival Although the invention has been described with reference to the presently preferred embodiment, it should be understood that various modifications can be made without departing from the spirit of the invention: Accordingly, the invention is limited only by the following claims.
Claims (51)
1. An electrode apparatus for the application of electric fields to a selected portion of a living body, comprising:
support means;
an array of multiple opposed pairs of electrodes mounted on said support means in spaced relation to one another, at least one of said pairs of electrodes having a needle configuration for penetrating tissue for in vivo electroporation of cells of the tissue;
and an electric pulse generator for applying pulses of high amplitude electric signals to selected opposed pairs of said electrodes proportionate to the distance between said electrodes for electroporation of cells between said electrodes.
support means;
an array of multiple opposed pairs of electrodes mounted on said support means in spaced relation to one another, at least one of said pairs of electrodes having a needle configuration for penetrating tissue for in vivo electroporation of cells of the tissue;
and an electric pulse generator for applying pulses of high amplitude electric signals to selected opposed pairs of said electrodes proportionate to the distance between said electrodes for electroporation of cells between said electrodes.
2. An apparatus according to claim 1, wherein one of said needle electrodes comprises a cannula for the introduction of molecules into said tissue.
3. An apparatus according to claim 2, wherein said support means comprises a hub mounted on said support and said electrodes are a circular array of needles supported on said hub.
4. An apparatus according to claim 1, wherein said support means comprises a hub mounted on a shaft and said electrodes are needles in a circular array supported on said hub.
5. An apparatus according to claim 4, wherein said apparatus includes a rotary switch selectively positionable for connecting alternate opposite pairs of electrodes to said pulse generator.
6. An apparatus according to claim 1, wherein the field generator generates an electric field having a strength of between approximately 0.2 kV/cm and 20 kV/cm and between approximately one pulse and one hundred pulses for application to a tissue.
7. An electrode apparatus for the application of electric fields to a selected portion of a living body, comprising:
support means;
an array of electrodes mounted on said support means in spaced relation to one another, at least a plurality of said electrodes having a needle configuration for penetrating tissue for in vivo electroporation of cells of the tissue; and an electric pulse generator for applying pulses of high amplitude electric signals to the electrodes proportionate to the distance between said electrodes for electroporation of cells between said electrodes, wherein said array of electrodes comprises a circular array of needle electrodes, and a switch assembly for selectively changing the polarity of opposing ones of said electrodes.
support means;
an array of electrodes mounted on said support means in spaced relation to one another, at least a plurality of said electrodes having a needle configuration for penetrating tissue for in vivo electroporation of cells of the tissue; and an electric pulse generator for applying pulses of high amplitude electric signals to the electrodes proportionate to the distance between said electrodes for electroporation of cells between said electrodes, wherein said array of electrodes comprises a circular array of needle electrodes, and a switch assembly for selectively changing the polarity of opposing ones of said electrodes.
8. An apparatus according to claim 7, wherein at least one of said needle electrodes has a cannula for injecting molecules into said tissue.
9. An apparatus according to claim 7, wherein said electrodes comprises a pair of tubular needles for inserting into selected tissue, and conductors insertable through said needles into said tissue.
10. An apparatus according to claim 9, wherein said needles are removable over said conductors.
11. A needle electrode assembly of needle electrodes for the application of electric fields to a selected portion of a living body, comprising:
a first combination needle electrode for insertion into selected tissue for injecting molecules into said tissue and for functioning as a first electrode;
a second combination of multiple needle electrodes for insertion into said selected tissue spaced from said first electrode, at least one of said multiple electrodes functioning as a second electrode in relation to said first electrode; and means for selectively connecting multiple pairs of said needle electrodes in pairs of opposed polarity to an electric pulse generator for applying pulses of high amplitude electric signals to the electrodes proportionate to the distance between said electrodes for in vivo electroporation of cells between said electrodes.
a first combination needle electrode for insertion into selected tissue for injecting molecules into said tissue and for functioning as a first electrode;
a second combination of multiple needle electrodes for insertion into said selected tissue spaced from said first electrode, at least one of said multiple electrodes functioning as a second electrode in relation to said first electrode; and means for selectively connecting multiple pairs of said needle electrodes in pairs of opposed polarity to an electric pulse generator for applying pulses of high amplitude electric signals to the electrodes proportionate to the distance between said electrodes for in vivo electroporation of cells between said electrodes.
12. An apparatus according to claim 11, wherein said first and one of said second needle electrodes comprises a pair of tubular needles for inserting into selected tissue, and said electrodes are separable conductors insertable through said needles into said tissue.
13. An apparatus according to claim 12, wherein said needles are removable over said electrodes.
14. An apparatus according to claim 11, further comprising switching means selectively positionable for connecting alternate opposite pairs of electrodes to said pulse generator.
15. An electrode apparatus for the application of electric fields to a selected portion of a living body, comprising:
an array of multiple pairs of electrodes at least multiple pairs of said electrodes having a needle configuration for penetrating selected tissue in spaced relation for in vivo electroporation of cells of the tissue; and an electric pulse generator for selectively applying pulses of high amplitude electric signals to selected opposed pairs of said electrodes proportionate to the distance between said selected pairs of electrodes for electroporation of cells between said selected pairs of electrodes.
an array of multiple pairs of electrodes at least multiple pairs of said electrodes having a needle configuration for penetrating selected tissue in spaced relation for in vivo electroporation of cells of the tissue; and an electric pulse generator for selectively applying pulses of high amplitude electric signals to selected opposed pairs of said electrodes proportionate to the distance between said selected pairs of electrodes for electroporation of cells between said selected pairs of electrodes.
16. An apparatus according to claim 15, wherein said pairs of needle electrodes comprises a pair of tubular needles for inserting into selected tissue, and separable conductors insertable through said needles into said tissue.
17. An apparatus according to claim 16, wherein said needles are removable over said conductors.
18. An apparatus according to claim 15, further comprising switch means selectively positionable for connecting alternate opposite pairs of electrodes to said pulse generator.
19. An apparatus according to claim 1, wherein said array of electrodes comprises:
a plurality of needle electrodes in at least a first row and a plurality of needle electrodes in at least a second row; and switching means operative for selectively connecting multiple needle electrodes in said first row in a first polarity and multiple needle electrodes in said second row in a second polarity.
a plurality of needle electrodes in at least a first row and a plurality of needle electrodes in at least a second row; and switching means operative for selectively connecting multiple needle electrodes in said first row in a first polarity and multiple needle electrodes in said second row in a second polarity.
20. An apparatus according to claim 19, wherein said multiple needle electrodes comprise at least two electrodes in each of said first and second rows.
21. An apparatus according to claim 20, wherein said multiple needle electrodes comprise at least five electrodes in each of said first and second rows.
22. A needle electrode assembly for the application of electric fields to a selected portion of a living body, comprising:
a support member;
an array of multiple needle electrodes mounted on said support structure in spaced relation to one another, at least a plurality of said electrodes comprising multiple needles arranged in a rectangular configuration in at least first and second parallel rows; and an electrical circuit including switching means connected to said electrodes for selectively connecting at least a first plurality of said electrodes in one of said first and second rows in a first polarity and at least a second plurality of electrodes in the other of said first and second rows in an opposite polarity to a pulse generator for applying pulses of high amplitude electric signals to said first and second plurality of said electrodes proportionate to the distance between said electrodes for electroporation of cells in tissue between said electrodes, at least one electrode of a pair of said electrodes connectable with an adjacent electrode to define one of a second pair of electrodes.
a support member;
an array of multiple needle electrodes mounted on said support structure in spaced relation to one another, at least a plurality of said electrodes comprising multiple needles arranged in a rectangular configuration in at least first and second parallel rows; and an electrical circuit including switching means connected to said electrodes for selectively connecting at least a first plurality of said electrodes in one of said first and second rows in a first polarity and at least a second plurality of electrodes in the other of said first and second rows in an opposite polarity to a pulse generator for applying pulses of high amplitude electric signals to said first and second plurality of said electrodes proportionate to the distance between said electrodes for electroporation of cells in tissue between said electrodes, at least one electrode of a pair of said electrodes connectable with an adjacent electrode to define one of a second pair of electrodes.
23. An apparatus according to claim 22, wherein said multiple needle electrodes comprise at least two electrodes in each of said first and second rows.
24. An apparatus according to claim 22, wherein said multiple needle electrodes comprise at least five electrodes in each of said first and second rows.
25. An electrode apparatus for the application of electric fields to a selected portion of a living body, comprising:
a support member;
an array of multiple electrodes mounted on said support structure in spaced relation to one another, at least one of said electrodes having a needle configuration for penetrating tissue for in vivo electroporation of cells of the tissue; and an electrical circuit connected to said electrodes and including switching means for selectively connecting said electrodes in opposing pairs of opposite polarity to a pulse generator for applying pulses of high amplitude electric signals to alternate opposed pairs of said electrodes proportionate to the distance between said electrodes for electroporation of cells between said electrodes, at least one electrode of a pair of said electrodes connectable with another electrode to define one of a second pair of electrodes.
a support member;
an array of multiple electrodes mounted on said support structure in spaced relation to one another, at least one of said electrodes having a needle configuration for penetrating tissue for in vivo electroporation of cells of the tissue; and an electrical circuit connected to said electrodes and including switching means for selectively connecting said electrodes in opposing pairs of opposite polarity to a pulse generator for applying pulses of high amplitude electric signals to alternate opposed pairs of said electrodes proportionate to the distance between said electrodes for electroporation of cells between said electrodes, at least one electrode of a pair of said electrodes connectable with another electrode to define one of a second pair of electrodes.
26. An apparatus according to claim 25, wherein said needle electrode comprises a cannula for the introduction of molecules into said tissue.
27. An apparatus according to claim 25, wherein said support member comprises a hub and said electrodes are needles in a circular array supported on said hub.
28. An apparatus according to claim 27, wherein said switching means comprises a switch assembly including a rotary switch selectively positionable for connecting alternate opposite pairs of electrodes to said pulse generator.
29. An apparatus according to claim 28, wherein said switch comprises means for connecting each electrode in a pair with each adjacent electrode.
30. An apparatus according to claim 29, wherein said pairs of electrodes define corners of a rectangle.
31. An apparatus according to claim 27, wherein said pairs of electrodes define corners of a rectangle.
32. An apparatus according to claim 25, wherein all said electrodes are needle electrodes.
33. An apparatus according to claim 32, wherein said pairs of electrodes define corners of a rectangle.
34. An apparatus according to claim 32, wherein said switch comprises means for connecting each electrode in a pair with each adjacent electrode.
35. An apparatus according to claim 34, wherein said pairs of electrodes define corners of a rectangle.
36. An apparatus according to claim 25, wherein said pairs of electrodes are positioned to define corners of a rectangle.
37. An apparatus according to claim 36, wherein:
said electrodes are needle electrodes mounted on said support member in a circular array; and said switch comprises means for connecting each electrode in a pair with each adjacent electrode.
said electrodes are needle electrodes mounted on said support member in a circular array; and said switch comprises means for connecting each electrode in a pair with each adjacent electrode.
38. A needle electrode assembly for the application of electric fields to a selected portion of a living body, comprising:
a support member;
an array of multiple electrodes mounted on said support structure in spaced relation to one another, at least a plurality of said electrodes comprising needles arranged in a rectangular configuration; and an electrical circuit including switching means connected to said electrodes for selectively connecting said electrodes in opposing pairs of opposite polarity to a pulse generator for applying pulses of high amplitude electric signals to alternate opposed pairs of said electrodes proportionate to the distance between said electrodes for electroporation of cells in tissue between said electrodes, at least one electrode of a pair of said electrodes connectable with an adjacent electrode to define one of a second pair of electrodes.
a support member;
an array of multiple electrodes mounted on said support structure in spaced relation to one another, at least a plurality of said electrodes comprising needles arranged in a rectangular configuration; and an electrical circuit including switching means connected to said electrodes for selectively connecting said electrodes in opposing pairs of opposite polarity to a pulse generator for applying pulses of high amplitude electric signals to alternate opposed pairs of said electrodes proportionate to the distance between said electrodes for electroporation of cells in tissue between said electrodes, at least one electrode of a pair of said electrodes connectable with an adjacent electrode to define one of a second pair of electrodes.
39. An apparatus according to claim 38, wherein at least one of said needle electrodes has a cannula for the introduction of molecules into tissue.
40. An apparatus according to claim 38, wherein said support member comprises a hub and said electrodes are needles mounted in a circular array on said hub.
41. An apparatus according to claim 40, wherein said switching means comprises a switch assembly including a rotary switch selectively positionable for connecting alternate opposite pairs of electrodes to said pulse generator.
42. An apparatus according to claim 38, wherein said switching means comprises a switch assembly including a rotary switch selectively positionable for connecting alternate opposite pairs of electrodes to said pulse generator.
43. An apparatus according to claim 42, wherein said switching means is connectable for selectively changing the polarity of opposing pairs of said electrodes.
44. An apparatus according to claim 43, wherein at least one of said needle electrodes has a cannula for the introduction of molecules into tissue.
45. An apparatus according to claim 38, further comprising a pulse generator having a field strength of from about 0.05kV/cm to about 20kV/cm.
46. Use of electrodes for configuring an electrode array suitable for electroporation, comprising providing an electric pulse generator and an array of multiple electrodes; positioning at least two pairs of electrodes of said array of electrodes in conductive relation to a site of electroporation so that said site is between a first pair and a second pair of electrodes; connecting said electric pulse generator to said electrodes; and operating said electric pulse generator for applying pulses of high amplitude electric signals to the electrodes as opposed pairs in proportionate to the distance between said pairs of electrodes.
47. The use of claim 46, wherein said step of positioning said array of electrodes comprises positioning pairs of electrodes to define corners of a rectangle.
48. The use of claim 46, wherein said step of providing said array of electrodes comprises providing a central electrode of a first polarity and a plurality of electrodes of a second polarity encircling said central electrode.
49. The use of claim 48, comprising the step of providing a switch assembly including a rotary switch selectively positionable for connecting alternate opposite pairs of electrodes to said pulse generator.
50. The use of claim 46, wherein said step of providing said array of electrodes comprises providing an array of multiple needle electrodes, comprising a plurality of opposed pairs of needle electrodes, and said step of applying pulses to said electrodes including selectively applying pulses to opposing pairs of electrodes.
51. The use of claim 50, wherein said step of applying pulses to said array of electrodes comprises applying said pulses sequently to pairs of electrodes in said array.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/467,566 US5702359A (en) | 1995-06-06 | 1995-06-06 | Needle electrodes for mediated delivery of drugs and genes |
US08/467,566 | 1995-06-06 | ||
US08/537,265 | 1995-09-29 | ||
US08/537,265 US5993434A (en) | 1993-04-01 | 1995-09-29 | Method of treatment using electroporation mediated delivery of drugs and genes |
PCT/US1996/007470 WO1996039226A1 (en) | 1995-06-06 | 1996-05-22 | Method of treatment using electroporation-mediated delivery of drugs and genes |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2218255A1 CA2218255A1 (en) | 1996-12-12 |
CA2218255C true CA2218255C (en) | 2001-11-20 |
Family
ID=27042102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002218255A Expired - Fee Related CA2218255C (en) | 1995-06-06 | 1996-05-22 | Method of treatment using electroporation-mediated delivery of drugs and genes |
Country Status (12)
Country | Link |
---|---|
US (6) | US5993434A (en) |
EP (1) | EP0874663B1 (en) |
JP (1) | JPH11506630A (en) |
KR (1) | KR100260238B1 (en) |
CN (1) | CN1150950C (en) |
AT (1) | ATE185083T1 (en) |
AU (1) | AU702054B2 (en) |
CA (1) | CA2218255C (en) |
DE (1) | DE69604509T2 (en) |
ES (1) | ES2140096T3 (en) |
GR (1) | GR3031963T3 (en) |
WO (1) | WO1996039226A1 (en) |
Families Citing this family (277)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5702359A (en) * | 1995-06-06 | 1997-12-30 | Genetronics, Inc. | Needle electrodes for mediated delivery of drugs and genes |
US5993434A (en) * | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
EA002087B1 (en) * | 1997-04-03 | 2001-12-24 | Электрофект Ас | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle |
US6261281B1 (en) * | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
US5873849A (en) * | 1997-04-24 | 1999-02-23 | Ichor Medical Systems, Inc. | Electrodes and electrode arrays for generating electroporation inducing electrical fields |
CN1261807A (en) * | 1997-06-30 | 2000-08-02 | 罗纳-布朗克罗莱尔股份有限公司 | Improved method for transferring nucleic acid into the striped muscle and combination therefor |
AU8444698A (en) | 1997-06-30 | 1999-01-25 | Centre National De La Recherche Scientifique | Improved method for transferring nucleic acid into multicelled eukaryo tic organism cells and combination therefor |
US6216034B1 (en) | 1997-08-01 | 2001-04-10 | Genetronics, Inc. | Method of programming an array of needle electrodes for electroporation therapy of tissue |
US6055453A (en) | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
SE9704076D0 (en) * | 1997-11-06 | 1997-11-06 | Holdingbolaget Vid Goeteborgs | Method for permeabilization of cell structures and use thereof |
US6778853B1 (en) | 1997-12-17 | 2004-08-17 | University Of South Florida | Electroporation device |
FR2773326B3 (en) * | 1998-01-06 | 2000-05-12 | Michel Siros | DEVICE FOR AIDING THE TREATMENT OF LIVING CELLS IN A GIVEN MEDIUM |
US6009347A (en) * | 1998-01-27 | 1999-12-28 | Genetronics, Inc. | Electroporation apparatus with connective electrode template |
US6208893B1 (en) * | 1998-01-27 | 2001-03-27 | Genetronics, Inc. | Electroporation apparatus with connective electrode template |
US6391005B1 (en) | 1998-03-30 | 2002-05-21 | Agilent Technologies, Inc. | Apparatus and method for penetration with shaft having a sensor for sensing penetration depth |
US6219577B1 (en) | 1998-04-14 | 2001-04-17 | Global Vascular Concepts, Inc. | Iontophoresis, electroporation and combination catheters for local drug delivery to arteries and other body tissues |
ATE369877T1 (en) * | 1998-06-26 | 2007-09-15 | Genetronics Inc | SYNERGISM OF PHOTODYNAMIC AND ELECTROPERMEATION EFFECTS ON CELL VITALITY AS A NEW CYTOTOXIC AGENT |
US7922709B2 (en) | 1998-07-13 | 2011-04-12 | Genetronics, Inc. | Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation |
JP2002520101A (en) | 1998-07-13 | 2002-07-09 | ジェネトロニクス、インコーポレーテッド | Method and apparatus for localized delivery of electrically assisted cosmetic agents |
US6678556B1 (en) * | 1998-07-13 | 2004-01-13 | Genetronics, Inc. | Electrical field therapy with reduced histopathological change in muscle |
WO2000002621A1 (en) | 1998-07-13 | 2000-01-20 | Genetronics, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
GB9817078D0 (en) | 1998-08-05 | 1998-10-07 | Habib Nagy A | Device for liver surgery |
CA2341446C (en) | 1998-08-31 | 2008-10-07 | Johnson & Johnson Consumer Companies, Inc. | Electrotransport device comprising blades |
US6314316B1 (en) * | 1998-12-17 | 2001-11-06 | University Of South Florida | Nonpenetrating electroporation device and method |
US6937890B2 (en) | 1998-12-17 | 2005-08-30 | University Of South Florida | Nonpenetrating electroporation device |
US6713291B2 (en) * | 1999-01-28 | 2004-03-30 | Alan D. King | Electrodes coated with treating agent and uses thereof |
CN1191872C (en) | 1999-01-28 | 2005-03-09 | 塞托·帕尔斯科技公司 | Delivery of macromolecules into cells |
EP1171189B1 (en) | 1999-03-25 | 2016-05-11 | Inovio Pharmaceuticals, Inc. | Apparatus for reducing electroporation-mediated muscle reaction and pain response |
US6678558B1 (en) * | 1999-03-25 | 2004-01-13 | Genetronics, Inc. | Method and apparatus for reducing electroporation-mediated muscle reaction and pain response |
EP1171195B1 (en) | 1999-04-16 | 2005-03-16 | Johnson & Johnson Consumer Companies, Inc. | Electrotransport delivery system comprising internal sensors |
CN1068525C (en) * | 1999-04-23 | 2001-07-18 | 孙才均 | Hot-needle electrochemical therapeutic apparatus for treating tumor |
US6514762B1 (en) | 1999-04-23 | 2003-02-04 | New Mexico State University Technology Transfer Corporation | Delivery of nucleotides by electrochemical release |
CA2369329A1 (en) | 1999-05-10 | 2000-11-16 | Gunter A. Hofmann | Method of electroporation-enhanced delivery of active agents |
US7171264B1 (en) * | 1999-05-10 | 2007-01-30 | Genetronics, Inc. | Intradermal delivery of active agents by needle-free injection and electroporation |
US20050009717A1 (en) * | 1999-07-01 | 2005-01-13 | Lukenbach Elvin R. | Foaming make-up removing cleansing compositions |
US7074747B1 (en) | 1999-07-01 | 2006-07-11 | Johnson & Johnson Consumer Companies, Inc. | Cleansing compositions |
WO2001001949A1 (en) | 1999-07-01 | 2001-01-11 | Johnson And Johnson Consumer Companies, Inc. | Cleansing compositions |
US6762158B2 (en) | 1999-07-01 | 2004-07-13 | Johnson & Johnson Consumer Companies, Inc. | Personal care compositions comprising liquid ester mixtures |
US6326177B1 (en) | 1999-08-04 | 2001-12-04 | Eastern Virginia Medical School Of The Medical College Of Hampton Roads | Method and apparatus for intracellular electro-manipulation |
US6587718B2 (en) | 1999-10-08 | 2003-07-01 | Scimed Life Systems, Inc. | Iontophoretic delivery to heart tissue |
WO2001043817A1 (en) * | 1999-12-15 | 2001-06-21 | University Of South Florida | Electroporation device and method |
CA2395492A1 (en) * | 1999-12-22 | 2001-07-05 | Diana Wang | Method and apparatus for targeting localised electroporation |
MXPA02006658A (en) | 2000-01-07 | 2004-09-10 | Biowave Corp | Electro therapy method and apparatus. |
US20080033492A1 (en) * | 2000-01-07 | 2008-02-07 | Biowave Corporation | Electro-therapy method |
US7013179B2 (en) | 2000-01-07 | 2006-03-14 | Biowave Corporation | Percutaneous electrode array |
US7927612B2 (en) * | 2000-01-19 | 2011-04-19 | Baofa Yu | Combinations and methods for treating neoplasms |
AU2001228841A1 (en) * | 2000-01-27 | 2001-08-07 | The Mollennium Laboratories | Molecule transferring device, auxiliary for molecule transferring device, and molecule transferring method |
US7742811B2 (en) * | 2000-03-13 | 2010-06-22 | Onco Stim | Implantable device and method for the electrical treatment of cancer |
US8024048B2 (en) * | 2000-03-13 | 2011-09-20 | Ionix Medical Inc. | Method and device for treating cancer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy |
WO2002000278A2 (en) * | 2000-06-26 | 2002-01-03 | Microheart, Inc. | Method and apparatus for treating ischemic tissue |
US6846306B1 (en) * | 2000-10-10 | 2005-01-25 | Cold Spring Harbor Laboratory | Single cell electroporation |
SE0003841D0 (en) * | 2000-10-20 | 2000-10-20 | Daniel Chiu | A method and apparatus for penetration of lipid bilayer membranes |
US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
US6706016B2 (en) * | 2000-11-24 | 2004-03-16 | Ckm Diagnostics, Inc. | Nerve stimulator output control needle with depth determination capability and method of use |
US7101703B2 (en) | 2001-03-09 | 2006-09-05 | Cornell Research Foundation, Inc. | Electrofusion microelectrode |
WO2002072783A2 (en) * | 2001-03-12 | 2002-09-19 | Irm, Llc | Identification of cellular targets for biologically active molecules |
US6936469B2 (en) | 2001-03-22 | 2005-08-30 | Chromos Molecular Systems Inc. | Methods for delivering nucleic acid molecules into cells and assessment thereof |
US7294511B2 (en) | 2001-03-22 | 2007-11-13 | Chromos Molecular Systems, Inc. | Methods for delivering nucleic acid molecules into cells and assessment thereof |
US20030186390A1 (en) * | 2001-03-22 | 2003-10-02 | De Jong Gary | Methods for delivering nucleic acid molecules into cells and assessment thereof |
US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
EP1404233B1 (en) | 2001-06-12 | 2009-12-02 | Pelikan Technologies Inc. | Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties |
US7981056B2 (en) | 2002-04-19 | 2011-07-19 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
WO2002100254A2 (en) | 2001-06-12 | 2002-12-19 | Pelikan Technologies, Inc. | Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge |
US8337419B2 (en) * | 2002-04-19 | 2012-12-25 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7025774B2 (en) | 2001-06-12 | 2006-04-11 | Pelikan Technologies, Inc. | Tissue penetration device |
US7344507B2 (en) | 2002-04-19 | 2008-03-18 | Pelikan Technologies, Inc. | Method and apparatus for lancet actuation |
US7033371B2 (en) | 2001-06-12 | 2006-04-25 | Pelikan Technologies, Inc. | Electric lancet actuator |
US20040204669A1 (en) * | 2001-07-05 | 2004-10-14 | Hofmann Gunter A. | Apparatus for electroporation mediated delivery for drugs and genes |
DE60217393T2 (en) | 2001-11-27 | 2007-10-18 | Cellectricon Ab | METHOD FOR THE COMBINED PARALLEL INTRODUCTION OF AGENTS AND ELECTROPORATION FOR CELL STRUCTURES AND USE THEREOF |
WO2003047684A2 (en) * | 2001-12-04 | 2003-06-12 | University Of Southern California | Method for intracellular modifications within living cells using pulsed electric fields |
JP2005530695A (en) * | 2002-02-15 | 2005-10-13 | ザイコス インク. | Electroporation method for introducing physiologically active substances into cells |
US7245963B2 (en) * | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
US8209006B2 (en) * | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
DE10212008A1 (en) * | 2002-03-18 | 2003-10-09 | Aventis Behring Gmbh | needle holder |
US6912417B1 (en) | 2002-04-05 | 2005-06-28 | Ichor Medical Systmes, Inc. | Method and apparatus for delivery of therapeutic agents |
CN100455328C (en) | 2002-04-16 | 2009-01-28 | 塞托·帕尔斯科技公司 | Method of treating biological materials with translating electrical fields and electrode polarity reversal |
US7892185B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US7291117B2 (en) * | 2002-04-19 | 2007-11-06 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8221334B2 (en) | 2002-04-19 | 2012-07-17 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US9795334B2 (en) | 2002-04-19 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7909778B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7331931B2 (en) | 2002-04-19 | 2008-02-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8579831B2 (en) | 2002-04-19 | 2013-11-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7892183B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US7229458B2 (en) | 2002-04-19 | 2007-06-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7297122B2 (en) | 2002-04-19 | 2007-11-20 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7674232B2 (en) | 2002-04-19 | 2010-03-09 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7547287B2 (en) | 2002-04-19 | 2009-06-16 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8267870B2 (en) | 2002-04-19 | 2012-09-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling with hybrid actuation |
US7232451B2 (en) | 2002-04-19 | 2007-06-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7713214B2 (en) | 2002-04-19 | 2010-05-11 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with optical analyte sensing |
US7901362B2 (en) * | 2002-04-19 | 2011-03-08 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US8784335B2 (en) | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
US7976476B2 (en) | 2002-04-19 | 2011-07-12 | Pelikan Technologies, Inc. | Device and method for variable speed lancet |
US7491178B2 (en) | 2002-04-19 | 2009-02-17 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
US8360992B2 (en) | 2002-04-19 | 2013-01-29 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US20030198625A1 (en) * | 2002-04-19 | 2003-10-23 | Genteric, Inc. | Electroporation-mediated transfection of the salivary gland |
US7648468B2 (en) * | 2002-04-19 | 2010-01-19 | Pelikon Technologies, Inc. | Method and apparatus for penetrating tissue |
AU2003299471A1 (en) * | 2002-05-07 | 2004-05-13 | Kai Kroll | Method and device for treating concer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy |
US10130415B2 (en) * | 2002-06-10 | 2018-11-20 | Wisconsin Alumni Research Foundation | Circumferential electrode array for tissue ablation |
US20070265582A1 (en) * | 2002-06-12 | 2007-11-15 | University Of Southern California | Injection Devices for Unimpeded Target Location Testing |
US20050070841A1 (en) * | 2002-07-04 | 2005-03-31 | Inovio As | Electroporation device and injection apparatus |
US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
DE60332377D1 (en) | 2002-10-21 | 2010-06-10 | Eisai Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES MEDIATED BY THE HUMANE PAPILLOMA VIRUS |
US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
WO2004066903A2 (en) * | 2003-01-29 | 2004-08-12 | E-Pill Pharma Ltd. | Active drug delivery in the gastrointestinal tract |
US20050058701A1 (en) * | 2003-01-29 | 2005-03-17 | Yossi Gross | Active drug delivery in the gastrointestinal tract |
DE602004028463D1 (en) | 2003-05-30 | 2010-09-16 | Pelikan Technologies Inc | METHOD AND DEVICE FOR INJECTING LIQUID |
US7850621B2 (en) | 2003-06-06 | 2010-12-14 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
WO2006001797A1 (en) | 2004-06-14 | 2006-01-05 | Pelikan Technologies, Inc. | Low pain penetrating |
US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
US7330851B2 (en) * | 2003-08-18 | 2008-02-12 | Eaglehawk, Limited | Data security through dissembly of data elements or connections between elements |
US8282576B2 (en) | 2003-09-29 | 2012-10-09 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for an improved sample capture device |
US7521224B2 (en) * | 2003-09-30 | 2009-04-21 | The United States Of America As Represented By The Secretary Of The Navy | Microelectronic cell electroporation array |
EP1680014A4 (en) | 2003-10-14 | 2009-01-21 | Pelikan Technologies Inc | Method and apparatus for a variable user interface |
EP1706026B1 (en) | 2003-12-31 | 2017-03-01 | Sanofi-Aventis Deutschland GmbH | Method and apparatus for improving fluidic flow and sample capture |
US7822454B1 (en) | 2005-01-03 | 2010-10-26 | Pelikan Technologies, Inc. | Fluid sampling device with improved analyte detecting member configuration |
PT1729848E (en) | 2004-03-08 | 2015-08-28 | Ichor Medical Systems Inc | Improved apparatus for electrically mediated delivery of therapeutic agents |
JP2005278480A (en) * | 2004-03-29 | 2005-10-13 | Fujitsu Ltd | Device for introducing material and tip for introducing material |
ES2611284T3 (en) | 2004-04-01 | 2017-05-08 | The General Hospital Corporation | Device for skin treatment and tissue remodeling |
US7720549B2 (en) * | 2004-04-06 | 2010-05-18 | Oncostim, Inc. | Partially implantable system for the electrical treatment of abnormal tissue growth |
US20050222646A1 (en) * | 2004-04-06 | 2005-10-06 | Kai Kroll | Method and device for treating cancer with modified output electrical therapy |
JP4504082B2 (en) * | 2004-04-28 | 2010-07-14 | 富士通株式会社 | Liquid injection device |
EP1751546A2 (en) | 2004-05-20 | 2007-02-14 | Albatros Technologies GmbH & Co. KG | Printable hydrogel for biosensors |
US7212865B2 (en) * | 2004-05-25 | 2007-05-01 | Philip Cory | Nerve stimulator and method |
EP1765194A4 (en) | 2004-06-03 | 2010-09-29 | Pelikan Technologies Inc | Method and apparatus for a fluid sampling device |
US9775553B2 (en) | 2004-06-03 | 2017-10-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
US6897069B1 (en) | 2004-06-08 | 2005-05-24 | Ambion, Inc. | System and method for electroporating a sample |
WO2005123182A2 (en) * | 2004-06-11 | 2005-12-29 | University Of South Florida | Nervous tissue electrode device |
EP1766004B1 (en) | 2004-06-12 | 2016-08-31 | Invitrogen Singapore Pte. Ltd. | Electroporator having an elongated hollow member |
TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
JP5197006B2 (en) * | 2004-06-24 | 2013-05-15 | スフェルゲン | Devices that move molecules to cells using electrical force |
FR2880808A1 (en) | 2005-01-20 | 2006-07-21 | Yves Scherman | Active material e.g. nucleotide, delivering device for providing e.g. chemotherapy, has electric current generator, electrodes connected to respective terminals of current generator and injection needle centered between electrodes |
FR2872056B1 (en) | 2004-06-24 | 2007-08-10 | Yves Scherman | DEVICE FOR DELIVERING ACTIVE PRINCIPLE TO CELLS AND TISSUES USING ONE OR TWO PHYSICAL FORCES |
JP2006102255A (en) * | 2004-10-06 | 2006-04-20 | Nippon Sherwood Medical Industries Ltd | Connecting structure of infusion line and connector with the connecting structure |
US20060165668A1 (en) * | 2004-12-10 | 2006-07-27 | Liu Linda N | Genetically modified tumor cells as cancer vaccines |
US8652831B2 (en) | 2004-12-30 | 2014-02-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte measurement test time |
GB0502384D0 (en) * | 2005-02-04 | 2005-03-16 | Instrumedical Ltd | Electro-surgical needle apparatus |
WO2007012907A2 (en) * | 2005-02-08 | 2007-02-01 | Allen, John | Electric therapy machine |
JP2008540023A (en) * | 2005-05-19 | 2008-11-20 | イー−ピル ファーマ リミティド | Ingestible device for nitric oxide production in tissues |
US8524678B2 (en) | 2005-05-31 | 2013-09-03 | The Regents Of The University Of Colorado, A Body Corporate | Method for delivering genes |
US7933648B2 (en) * | 2005-07-21 | 2011-04-26 | Naim Erturk Tanrisever | High voltage transcutaneous electrical stimulation device and method |
US7647122B2 (en) * | 2005-07-26 | 2010-01-12 | Medtronic, Inc. | Surgical needle driver |
DE102005062933A1 (en) * | 2005-08-24 | 2007-03-22 | Triton Gmbh | A method of treating cellular structure in the meat, meat by-product, fish and seafood food processing industries |
US20070083075A1 (en) * | 2005-10-12 | 2007-04-12 | Moshe Ein-Gal | Method and apparatus for applying energy to tissues |
US20070142885A1 (en) * | 2005-11-29 | 2007-06-21 | Reliant Technologies, Inc. | Method and Apparatus for Micro-Needle Array Electrode Treatment of Tissue |
CN101370927A (en) * | 2005-12-07 | 2009-02-18 | 基因特伦尼克斯公司 | Variable volume electroporation chamber and methods therefore |
US7915044B2 (en) * | 2005-12-22 | 2011-03-29 | Cornell Research Foundation, Inc. | Electrofusion microelectrode and methods of using it to manipulate cells and/or cellular components |
JP4614451B2 (en) * | 2005-12-26 | 2011-01-19 | 日本シャーウッド株式会社 | Medical suture tool |
CN109621078B (en) * | 2006-02-09 | 2022-05-27 | 德卡产品有限公司 | System for controlling a wearable medical device |
CN101370553B (en) * | 2006-02-11 | 2013-04-10 | 基因特伦尼克斯公司 | Device and method for single-needle in vivo electroporation |
KR101529448B1 (en) * | 2006-03-03 | 2015-06-18 | 온코섹 메디컬 인코포레이티드 | Device for treating microscopic residual tumors remaining in tissues following surgical resection |
JPWO2007123142A1 (en) * | 2006-04-20 | 2009-09-03 | Tti・エルビュー株式会社 | Iontophoresis device |
US20080119797A1 (en) * | 2006-11-20 | 2008-05-22 | Stanley Kim | System with a syringe device and a needle device |
US20080139989A1 (en) * | 2006-12-11 | 2008-06-12 | Stanley Kim | Hemodialysis needle device having multiple needles mounted on a needle hub |
US20070276425A1 (en) * | 2006-05-29 | 2007-11-29 | Stanley Kim | Painless Blood Sampling Lancet with Bundled Multiple Thin Needles |
EP1862125B1 (en) * | 2006-05-31 | 2011-08-03 | Covidien AG | Medical suturing tool with gripping device |
DE602007003723D1 (en) * | 2006-06-12 | 2010-01-21 | Region Hovedstaden V Herlev Ho | ELEKTRODENEINFÜHREINRICHTUNG |
CN101138634A (en) | 2006-09-07 | 2008-03-12 | 于保法 | Composition for treating tumour |
JP4536698B2 (en) * | 2006-10-05 | 2010-09-01 | 日本シャーウッド株式会社 | Medical suture tool |
WO2008052198A2 (en) * | 2006-10-26 | 2008-05-02 | Reliant Technologies, Inc. | Methods of increasing skin permeability by treatment with electromagnetic radiation |
WO2008118212A2 (en) | 2006-11-08 | 2008-10-02 | Veritas, Llc | In vivo delivery of double stranded rna to a target cell |
JP4565576B2 (en) * | 2007-02-20 | 2010-10-20 | 日本シャーウッド株式会社 | Puncture needle assist tool |
US20080312648A1 (en) * | 2007-06-12 | 2008-12-18 | Darion Peterson | Fat removal and sculpting device |
GB2464902B (en) | 2007-08-14 | 2011-10-19 | Hutchinson Fred Cancer Res | Methods for evaluating candidate therapeutic agents |
DE102008008614A1 (en) | 2008-02-12 | 2009-08-13 | Leibniz-Institut für Plasmaforschung und Technologie e.V. | Plama device for the selective treatment of electroporated cells |
JP5873717B2 (en) * | 2008-04-04 | 2016-03-01 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Vaccine and immunotherapeutic agent using IL-28 and composition and method of use thereof |
WO2009124312A2 (en) * | 2008-04-04 | 2009-10-08 | The Trustees Of The University Of Pennsylvania | Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same |
WO2009126900A1 (en) | 2008-04-11 | 2009-10-15 | Pelikan Technologies, Inc. | Method and apparatus for analyte detecting device |
KR101084528B1 (en) | 2008-04-15 | 2011-11-18 | 인비트로겐 싱가포르 피티이. 엘티디. | Pipette tip for electroporation device |
WO2009137609A2 (en) | 2008-05-06 | 2009-11-12 | Cellutions, Inc. | Apparatus and systems for treating a human tissue condition |
JP5185706B2 (en) * | 2008-06-24 | 2013-04-17 | 日本コヴィディエン株式会社 | Puncture needle assist tool |
US9597145B2 (en) | 2008-08-20 | 2017-03-21 | Prostacare Pty Ltd | Non-thermal ablation system for treating tissue |
US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
US20100286587A1 (en) * | 2009-05-07 | 2010-11-11 | Yossi Gross | Sublingual electrical drug delivery |
US8414559B2 (en) | 2009-05-07 | 2013-04-09 | Rainbow Medical Ltd. | Gastroretentive duodenal pill |
US20100298825A1 (en) * | 2009-05-08 | 2010-11-25 | Cellutions, Inc. | Treatment System With A Pulse Forming Network For Achieving Plasma In Tissue |
EP2453856B1 (en) | 2009-07-15 | 2019-02-20 | NewSouth Innovations Pty Limited | Agent provided to the cochlea and cochlear implant |
DE102009028462A1 (en) | 2009-08-11 | 2011-03-24 | Leibniz-Institut für Plasmaforschung und Technologie e.V. | Apparatus and method for the treatment of living cells by means of a plasma |
CN102821790A (en) | 2009-09-14 | 2012-12-12 | 宾夕法尼亚大学托管会 | Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same |
US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
CA2810514C (en) * | 2010-09-09 | 2021-05-04 | Old Dominion University Research Foundation | Multi-electrode electrical pulse delivery system for treatment of biological tissues |
WO2012041867A2 (en) | 2010-09-27 | 2012-04-05 | China Agricultural University | Combined antigen and dna vaccine for preventing and treating autoimmune diseases |
EP2670426B1 (en) | 2011-01-31 | 2017-05-10 | The General Hospital Corporation | Multimodal trail molecules and uses in cellular therapies |
CN102631243B (en) * | 2011-02-15 | 2014-09-17 | 成功大学 | Therapeutic device for electromagnetic thermotherapy |
WO2012158132A1 (en) | 2011-05-18 | 2012-11-22 | Eteka Llc | Apparatus for the enhancement of food properties by electroporation or pulsed electric fields |
CA2839196A1 (en) | 2011-06-15 | 2012-12-20 | Chrontech Pharma Ab | Injection needle and device |
CN102284132A (en) * | 2011-06-30 | 2011-12-21 | 杭州电子科技大学 | High-voltage pulse electric field treatment device based on multiple needle electrodes |
CN102284135A (en) * | 2011-06-30 | 2011-12-21 | 杭州电子科技大学 | High-voltage pulse electric field therapy apparatus based on single needle-shaped electrodes |
CN104203287B (en) | 2011-07-12 | 2017-07-14 | 费城健康及教育公司,d/b/a,德雷克塞尔大学医学院 | New difficile dna vaccine |
MX2014003176A (en) | 2011-09-16 | 2015-08-05 | Univ Pennsylvania | Rna engineered t cells for the treatment of cancer. |
US9708384B2 (en) | 2011-09-22 | 2017-07-18 | The Trustees Of The University Of Pennsylvania | Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens |
WO2013063530A2 (en) | 2011-10-28 | 2013-05-02 | Presage Biosciences, Inc. | Methods for drug delivery |
WO2013063419A2 (en) | 2011-10-28 | 2013-05-02 | The Trustees Of The University Of Pennsylvania | A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
US10206997B2 (en) | 2011-11-10 | 2019-02-19 | Bin Wang | Facilitator-DNA combination vaccine |
US20130197425A1 (en) * | 2011-12-16 | 2013-08-01 | The Regents Of The University Of California | Current cage for reduction of a non-target tissue exposure to electric fields in electroporation based treatment |
CN103239734B (en) | 2012-02-10 | 2016-02-24 | 北京艾棣维欣生物技术有限公司 | For preventing and/or treating the vaccine of respiratory syncytial virus infection |
EP3747898B1 (en) | 2012-02-22 | 2023-03-15 | The Trustees of the University of Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
CA2864489C (en) | 2012-02-22 | 2023-08-08 | The Trustees Of The University Of Pennsylvania | Use of the cd2 signaling domain in second-generation chimeric antigen receptors |
WO2013166484A1 (en) * | 2012-05-04 | 2013-11-07 | Roger Khouri | Surgical tools and methods for their use |
BR112015000638A2 (en) | 2012-07-13 | 2017-08-08 | Univ Pennsylvania | isolated nucleic acid sequence, cell, methods for stimulating a cell-mediated immune response to a target cell or tissue population in a mammal, for providing antitumor immunity in a mammal, for treating a mammal having a disease, disorder or condition associated with high expression of a tumor antigen |
US9144459B2 (en) | 2012-07-19 | 2015-09-29 | Cook Medical Technologies Llc | Endoscopic ultrasound ablation needle |
WO2014035474A1 (en) | 2012-08-30 | 2014-03-06 | The General Hospital Corporation | Compositions and methods for treating cancer |
WO2014055442A2 (en) | 2012-10-01 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
WO2014093897A1 (en) | 2012-12-13 | 2014-06-19 | The Trustees Of The University Of Pennsylvania | Wt1 vaccine |
CA2902565C (en) | 2013-03-15 | 2022-11-29 | Loma Linda University | Treatment of autoimmune diseases |
US10098585B2 (en) | 2013-03-15 | 2018-10-16 | Cadwell Laboratories, Inc. | Neuromonitoring systems and methods |
JP6649250B2 (en) | 2013-05-21 | 2020-02-19 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Engineered heme binding constructs and uses thereof |
EP3028048B1 (en) | 2013-07-31 | 2018-09-26 | BioVentures, LLC | Compositions for treating and preventing cancer targeting tumor associated carbohydrate antigens |
CN111012905B (en) | 2013-10-07 | 2023-12-22 | 宾夕法尼亚大学理事会 | Vaccine with interleukin-33 as an adjuvant |
CA2930695A1 (en) | 2013-11-14 | 2015-05-21 | Inovio Pharmaceuticals, Inc. | Hiv-1 env dna vaccine plus protein boost |
CA2932055A1 (en) | 2013-11-29 | 2015-06-04 | The Trustees Of The University Of Pennsylvania | Mers-cov vaccine |
CA2935375C (en) | 2014-01-06 | 2023-08-08 | The Trustees Of The University Of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
ES2963718T3 (en) | 2014-01-21 | 2024-04-01 | Novartis Ag | Antigen-presenting capacity of CAR-T cells enhanced by co-introduction of co-stimulatory molecules |
CN105940110A (en) | 2014-01-31 | 2016-09-14 | 菲克特生物科学股份有限公司 | Methods and products for nucleic acid production and delivery |
JP6737778B2 (en) | 2014-10-01 | 2020-08-12 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Vaccine with antigen and interleukin-21 as adjuvant |
CN114836385A (en) | 2014-10-31 | 2022-08-02 | 宾夕法尼亚大学董事会 | Altering gene expression in CART cells and uses thereof |
ES2910227T3 (en) | 2014-10-31 | 2022-05-12 | Univ Pennsylvania | Composition and methods for the stimulation and expansion of T cells |
EP3223810A1 (en) | 2014-11-26 | 2017-10-04 | Baofa Yu | Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy |
EP3799879A1 (en) * | 2015-01-09 | 2021-04-07 | OncoSec Medical Incorporated | Gene therapy using co-stimulatory molecule and cytokine for the treatment of malignancies |
US11116838B2 (en) | 2015-01-29 | 2021-09-14 | The Trustees Of The University Of Pennsylvania | Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy |
WO2016122738A1 (en) | 2015-01-31 | 2016-08-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for t cell delivery of therapeutic molecules |
EP3256585A4 (en) | 2015-02-13 | 2018-08-15 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
US20180112006A1 (en) | 2015-04-17 | 2018-04-26 | The General Hospital Corporation | Agents, systems and methods for treating cancer |
AU2016257721B2 (en) | 2015-05-01 | 2019-11-14 | The Regents Of The University Of California | Glycan-dependent immunotherapeutic molecules |
CN108348551A (en) | 2015-08-28 | 2018-07-31 | 宾夕法尼亚大学董事会 | Express the method and composition of the cell of signal transduction molecule in chimeric cell |
KR101788301B1 (en) * | 2015-09-17 | 2017-10-20 | 주식회사 엘림텍 | Electroporation device and control method thereof |
JP6292705B2 (en) | 2016-02-22 | 2018-03-14 | 公益財団法人東京都医学総合研究所 | Electroporation electrode |
US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
KR102624967B1 (en) | 2016-04-29 | 2024-01-16 | 이노비오 파마수티컬즈, 인크. | The in vivo use of chondroitinase and/or hyaluronidase to enhance delivery of an agent |
US10233419B2 (en) | 2016-06-30 | 2019-03-19 | Zymergen Inc. | Apparatuses and methods for electroporation |
JP2018035137A (en) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag | Novel anti-fibroblast activated protein (FAP) binding agent and use thereof |
US10576167B2 (en) | 2016-08-17 | 2020-03-03 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
US9935395B1 (en) | 2017-01-23 | 2018-04-03 | Cadwell Laboratories, Inc. | Mass connection plate for electrical connectors |
GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
WO2019104326A1 (en) | 2017-11-27 | 2019-05-31 | Prostacare Pty Ltd | An apparatus and a method for the treatment of a prostatic disease |
JP2021508533A (en) | 2017-12-26 | 2021-03-11 | ギャラリー,インコーポレイテッド | Optimizing energy delivery for a variety of applications |
AU2018396083A1 (en) | 2017-12-29 | 2020-05-21 | Cellectis | Method for improving production of CAR T cells |
WO2019160897A1 (en) | 2018-02-13 | 2019-08-22 | Purdue Research Foundation | Inactivating bacteria with electric pulses and antibiotics |
WO2019168949A1 (en) | 2018-02-28 | 2019-09-06 | Prostacare Pty Ltd | System for managing high impedance changes in a non-thermal ablation system for bph |
US11577071B2 (en) | 2018-03-13 | 2023-02-14 | Pulse Biosciences, Inc. | Moving electrodes for the application of electrical therapy within a tissue |
US11253182B2 (en) | 2018-05-04 | 2022-02-22 | Cadwell Laboratories, Inc. | Apparatus and method for polyphasic multi-output constant-current and constant-voltage neurophysiological stimulation |
US11443649B2 (en) | 2018-06-29 | 2022-09-13 | Cadwell Laboratories, Inc. | Neurophysiological monitoring training simulator |
WO2020092455A2 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
ES2949058T3 (en) * | 2018-11-05 | 2023-09-25 | Region Hovedstaden V/Herlev Hospital | A set of electrodes to improve the distribution of the electric field |
AU2020218502B2 (en) * | 2019-02-04 | 2022-03-03 | Rutgers, The State University Of New Jersey | Device for tissue electrotransfer using a microelectrode |
WO2020191102A1 (en) | 2019-03-18 | 2020-09-24 | The Broad Institute, Inc. | Type vii crispr proteins and systems |
WO2020198413A1 (en) | 2019-03-27 | 2020-10-01 | The Trustees Of The University Of Pennsylvania | Tn-muc1 chimeric antigen receptor (car) t cell therapy |
US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
TW202128775A (en) | 2019-10-16 | 2021-08-01 | 英商阿法克塔生命科學有限公司 | Pd-l1 inhibitor - tgfβ inhibitor bispecific drug moieties |
KR20220157969A (en) | 2020-02-25 | 2022-11-29 | 이노비오 파마수티컬즈, 인크. | Coronavirus vaccine and how to use it |
WO2021178896A1 (en) | 2020-03-06 | 2021-09-10 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
CN111317558A (en) * | 2020-03-12 | 2020-06-23 | 北京三春晖医疗器械有限公司 | Tumor ablation equipment using ultrahigh-voltage positive-negative composite pulse electric field |
CA3172447A1 (en) | 2020-03-27 | 2021-09-30 | Erik Hans MANTING | In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
JP2023519346A (en) | 2020-03-27 | 2023-05-10 | メンドゥス・ベスローテン・フェンノートシャップ | Ex vivo (EX VIVO) use of leukemia-derived modified cells to enhance the efficacy of adoptive cell therapy |
MX2022014248A (en) | 2020-05-14 | 2022-12-02 | Inovio Pharmaceuticals Inc | Vaccines for recurrent respiratory papillomatosis and methods of using the same. |
GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
US20230272378A1 (en) | 2020-06-12 | 2023-08-31 | University Of Rochester | ENCODING AND EXPRESSION OF ACE-tRNAs |
US20230372484A1 (en) | 2020-09-14 | 2023-11-23 | Vor Biopharma Inc. | Chimeric antigen receptors for treatment of cancer |
WO2022097068A1 (en) | 2020-11-05 | 2022-05-12 | Dcprime B.V. | Use of tumor-independent antigens in immunotherapies |
WO2022187591A1 (en) | 2021-03-05 | 2022-09-09 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
AU2022235341A1 (en) | 2021-03-12 | 2023-09-21 | Mendus B.V. | Methods of vaccination and use of cd47 blockade |
WO2023010118A1 (en) | 2021-07-29 | 2023-02-02 | Vor Biopharma Inc. | Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same |
WO2023010126A2 (en) | 2021-07-29 | 2023-02-02 | Vor Biopharma Inc. | Chimeric antigen receptors for treatment of cancer |
CA3228178A1 (en) | 2021-08-05 | 2023-02-09 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
CA3230933A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-lamp1 antibodies and their uses |
AU2022339667A1 (en) | 2021-09-03 | 2024-04-11 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
WO2023150753A1 (en) | 2022-02-07 | 2023-08-10 | University Of Rochester | Optimized sequences for enhanced trna expression or/and nonsense mutation suppression |
US20240002800A1 (en) | 2022-05-16 | 2024-01-04 | Mendus B.V. | Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1099062A (en) * | 1913-12-10 | 1914-06-02 | Peter P Laposkey | Electric scalp appliance. |
DE863111C (en) * | 1951-07-03 | 1953-01-15 | Walter Hallegger | Instrument for transcutaneous and subcutaneous heating and iontophoresis and method of its use |
US4116238A (en) * | 1976-08-18 | 1978-09-26 | Midgard Electronics Company, Inc. | High voltage constant current source for iontophoresis |
US4528265A (en) * | 1982-05-11 | 1985-07-09 | Becker Robert O | Processes and products involving cell modification |
US4784737A (en) * | 1986-04-18 | 1988-11-15 | The United States Department Of Energy | Electromicroinjection of particles into living cells |
US5128257A (en) * | 1987-08-31 | 1992-07-07 | Baer Bradford W | Electroporation apparatus and process |
EP0398960B1 (en) | 1988-01-21 | 1995-12-06 | Massachusetts Institute Of Technology | Transport of molecules across tissue using electroporation |
US5389069A (en) * | 1988-01-21 | 1995-02-14 | Massachusetts Institute Of Technology | Method and apparatus for in vivo electroporation of remote cells and tissue |
US4955378A (en) | 1988-05-02 | 1990-09-11 | University Of South Florida | Apparatus and methods for performing electrofusion at specific anatomical sites |
WO1989010690A1 (en) * | 1988-05-02 | 1989-11-16 | University Of South Florida | Method for electrofusing biological particles to tissues |
ES2012944A6 (en) * | 1989-01-09 | 1990-04-16 | Tomas Justribo Jose Ramon | A device for the administration of medication by iontopheresis for local - regional treatment. |
CS275292B2 (en) * | 1989-02-22 | 1992-02-19 | Cvut Fakulta Elektrotechnick | Private rehabilitation apparatus with ion transcutaneous acceleration |
US5137817A (en) * | 1990-10-05 | 1992-08-11 | Amoco Corporation | Apparatus and method for electroporation |
US5279544A (en) * | 1990-12-13 | 1994-01-18 | Sil Medics Ltd. | Transdermal or interdermal drug delivery devices |
US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
US5468223A (en) * | 1992-11-30 | 1995-11-21 | C.N.R.S. Paris | Electrochemotherapy |
FR2703253B1 (en) * | 1993-03-30 | 1995-06-23 | Centre Nat Rech Scient | APPLICATOR OF ELECTRIC PULSES FOR TREATING BIOLOGICAL TISSUES. |
US5993434A (en) * | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
US5702359A (en) * | 1995-06-06 | 1997-12-30 | Genetronics, Inc. | Needle electrodes for mediated delivery of drugs and genes |
US5439440A (en) * | 1993-04-01 | 1995-08-08 | Genetronics, Inc. | Electroporation system with voltage control feedback for clinical applications |
US6041252A (en) * | 1995-06-07 | 2000-03-21 | Ichor Medical Systems Inc. | Drug delivery system and method |
EA002087B1 (en) * | 1997-04-03 | 2001-12-24 | Электрофект Ас | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle |
US6261281B1 (en) * | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
US5873849A (en) * | 1997-04-24 | 1999-02-23 | Ichor Medical Systems, Inc. | Electrodes and electrode arrays for generating electroporation inducing electrical fields |
US6009347A (en) * | 1998-01-27 | 1999-12-28 | Genetronics, Inc. | Electroporation apparatus with connective electrode template |
-
1995
- 1995-09-29 US US08/537,265 patent/US5993434A/en not_active Expired - Lifetime
-
1996
- 1996-05-22 EP EP96916550A patent/EP0874663B1/en not_active Expired - Lifetime
- 1996-05-22 KR KR1019970708424A patent/KR100260238B1/en not_active IP Right Cessation
- 1996-05-22 CA CA002218255A patent/CA2218255C/en not_active Expired - Fee Related
- 1996-05-22 WO PCT/US1996/007470 patent/WO1996039226A1/en active IP Right Grant
- 1996-05-22 AT AT96916550T patent/ATE185083T1/en not_active IP Right Cessation
- 1996-05-22 DE DE69604509T patent/DE69604509T2/en not_active Expired - Lifetime
- 1996-05-22 AU AU59259/96A patent/AU702054B2/en not_active Ceased
- 1996-05-22 ES ES96916550T patent/ES2140096T3/en not_active Expired - Lifetime
- 1996-05-22 CN CNB961946083A patent/CN1150950C/en not_active Expired - Fee Related
- 1996-05-22 JP JP9500675A patent/JPH11506630A/en active Pending
-
1999
- 1999-10-25 US US09/427,151 patent/US6451002B1/en not_active Expired - Lifetime
- 1999-11-25 GR GR990403056T patent/GR3031963T3/en unknown
-
2000
- 2000-04-18 US US09/551,327 patent/US6418341B1/en not_active Expired - Lifetime
-
2002
- 2002-01-17 US US10/053,861 patent/US6567694B2/en not_active Expired - Lifetime
- 2002-06-21 US US10/177,560 patent/US6569149B2/en not_active Expired - Lifetime
- 2002-08-06 US US10/213,514 patent/US6763264B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ATE185083T1 (en) | 1999-10-15 |
US20030097089A1 (en) | 2003-05-22 |
CN1187145A (en) | 1998-07-08 |
US6763264B2 (en) | 2004-07-13 |
CA2218255A1 (en) | 1996-12-12 |
WO1996039226A1 (en) | 1996-12-12 |
US6569149B2 (en) | 2003-05-27 |
JPH11506630A (en) | 1999-06-15 |
EP0874663A1 (en) | 1998-11-04 |
KR100260238B1 (en) | 2000-07-01 |
DE69604509T2 (en) | 2000-01-13 |
AU702054B2 (en) | 1999-02-11 |
US6567694B2 (en) | 2003-05-20 |
EP0874663B1 (en) | 1999-09-29 |
CN1150950C (en) | 2004-05-26 |
AU5925996A (en) | 1996-12-24 |
DE69604509D1 (en) | 1999-11-04 |
US20030009148A1 (en) | 2003-01-09 |
GR3031963T3 (en) | 2000-03-31 |
US6418341B1 (en) | 2002-07-09 |
US20020198485A1 (en) | 2002-12-26 |
US6451002B1 (en) | 2002-09-17 |
US5993434A (en) | 1999-11-30 |
ES2140096T3 (en) | 2000-02-16 |
KR19990021949A (en) | 1999-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2218255C (en) | Method of treatment using electroporation-mediated delivery of drugs and genes | |
US20050192542A1 (en) | Method of treatment using electroporation mediated delivery of drugs and genes | |
CA2268026C (en) | Method and apparatus for using electroporation mediated delivery of drugs and genes | |
US6241701B1 (en) | Apparatus for electroporation mediated delivery of drugs and genes | |
US6216034B1 (en) | Method of programming an array of needle electrodes for electroporation therapy of tissue | |
US20040204669A1 (en) | Apparatus for electroporation mediated delivery for drugs and genes | |
MXPA97008316A (en) | Method of treatment using administration of drugs and genes through electroporac |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20130522 |